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ABSTRACT 
 
The general aim of the thesis was to gain increased insight into the long-term prognosis for 
young women with breast cancer. 
 
In a population-based cohort of 22,017 women with breast cancer, we studied prognosis by 
age. Women aged <35 (n=471), 35–39 (n=858) and 40–49 (n=4789) were compared with 
women aged 50–69. The cumulative 5-year relative survival ratio (RSR) and the relative 
excess risk (RER) of mortality were calculated. Women <35 years of age had a worse 
survival than middle-aged women, partly explained by a later stage at diagnosis. After 
correction for stage, tumor characteristics and treatment, young age remained an 
independent risk factor for death. The excess risk of death in young women was only 
present in stage I-II disease and was most pronounced in women with small tumors.  
 
For in-depth studies on a large subpopulation from the original cohort (all 471 women aged 
<35 and a random sample of 700 women aged 35–69), we collected detailed data from the 
medical records, re-evaluated slides and produced TMAs from tumor tissue. Breast cancer-
specific survival (BCSS), distant disease-free survival (DDFS) and locoregional recurrence-
free survival (LRFS) by age were analysed. In a multivariate analysis, age <35 and age 35–
39 years conferred a risk in LRFS but not in DDFS and BCSS. The age-related differences 
in prognosis were most pronounced in early stage luminal Her2-negative tumors, where 
low age was an independent prognostic factor also for DDFS (HR 1.87 (1.03–3.44)).  
 
To study the importance of proliferation markers for the long-term prognosis in young 
women, protein expression of Ki-67, cyclin A2, B1, D1 and E1 was analysed in 504 women 
aged <40 and in 383 women aged ≥40. The higher expression of proliferation markers in 
young women did not have a strong impact on the prognosis. Proliferation markers are less 
important in young women, and Ki-67 was prognostic only in young women with Luminal 
PR+ tumors. Age <40 years was an independent risk factor of DDFS exclusively in this 
subgroup (adjusted HR 2.35 (1.22-4.50)). The only cyclin adding prognostic value beyond 
subtype in young women was cyclin E1.  
 
In a cohort of 469 women aged <40 and 360 women aged ≥40 we examined whether Her2 
status assessed by silver enhanced in situ hybridization (SISH) for all cases, would reveal a 
proportion of women undiagnosed by routine Her2 testing and whether this would affect 
their prognosis. With SISH testing for all women, the Her2-positive rate increased from 
20.0% to 24.4% (p<0.001), and similarly for women aged <40 and ≥40 years. Young women 
had Her2+ breast cancer twice as often as middle-aged women. Her2 amplification was 
present in 4.6% of cases scored 0 with IHC, while the corresponding proportions for scores 
1+, 2+ and 3+ were 36.0%, 83.7% and 96.8%, respectively. All Her2 amplified cases, both 
true positive and false negative, had a significantly worse BCSS than the true negative cases.  
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BACKGROUND 
 
Definition of young age 
In the scientific literature, there are several definitions of young age in breast cancer: <35 
years, <40 years, <50 years or premenopausal. In reality, it seems that age is a continuous 
variable and, the narrower definition applied, the larger will the age-related differences be. 
When diagnosed with breast cancer, women <35 and <40 years old share the same tumor 
characteristics and have a similar prognosis [1-3], whereas women 40-49 years old have the 
best survival rate from breast cancer [1,4]. Thus, a cut-off at age 50 will dilute the age-related 
differences. Age, rather than menopausal status, reflects the biological and aetiological 
entities associated with breast cancer in young women [5]. 
Epidemiology 
The median age at a breast cancer diagnosis in Sweden is 63. The risk of being diagnosed 
with breast cancer (cumulative incidence) before age 75 is 10.5%, or 1 in 9.5 women. Breast 
cancer in young women is rare, with a cumulative incidence at age 45 of 1.1%, or 1 in 91 
women [6]. In 2015, 417 women <40 years old (4.0% of all diagnosed cases) and 143 women 
<35 years old (1.5%) were diagnosed with breast cancer in Sweden [6]. That is in line with 
the rates in the Nordic countries as a whole (4.0%) [7], as well as in Europe (5.4%) and North 
America (5.6%) [8]. In South America, Asia and Africa, the longevity is shorter, which 
explains a larger proportion of young women with breast cancer in these parts of the world 
(Figure 1). 
 
Figure 1. Incidence of breast cancer at age 20-39 and mortality by geographic region. Grey bars 
indicate incidence, given as the proportion of all cases of female breast cancer. Red bars indicate 
mortality attributed to breast cancer, including a 5-year delay from diagnosis at age 20-44. *[8], 
**[7], ***[6,9] 
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In Sweden, the incidence of breast cancer has increased by 1.6% per year during the last 20 
years. For young women, however, there has been no increase, but rather a stabile incidence 
of 20-23 new cases per 100,000 women [6]. From a global perspective, there has been a 
dramatic increase in the incidence of breast cancer, with a rise of 43.0% from 2005 to 2015 
[10]. This increase is due to population growth (12.6%), to change in age structure (15%) and 
to a true change in the incidence rate (14.9%). A study based on the Surveillance 
Epidemiology and End Results (SEER) data showed that between 2000 and 2009, the 
incidence of oestrogen (ER)+ breast cancer increased in women <40 years, while the 
incidence of ER- breast cancer decreased [11]. 
 
Despite breast cancer being rare in young women, it is the most frequent type of cancer 
diagnosed in this age group. In Swedish women aged 20-39, breast cancer accounted for 
27.2% (386 of 1417) of all cancers diagnosed. The corresponding proportion for women of all 
ages was 31.4% (9730 of 30970) [6]. 
 
Although the incidence has increased over time, the mortality has decreased considerably over 
the last few decades due to early diagnosis and better treatment. In young women, however, 
breast cancer is still the leading cause of death from cancer and the third most common 
cause of death overall after suicide and road injuries [9]. 
 
Risk factors for developing breast cancer at a young age 
Breast cancer in young women has a somewhat different panorama of risk factors to those in 
middle-aged women. Young women have a shorter exposure to risk factors associated with 
the disease, but they may instead be more sensitive to some risk factors. Many of these risk 
estimates concern young women in a wider perspective, defined as premenopausal women. 
 
Previous chest radiotherapy  
Women with previous radiotherapy at a young age (10-30 years) have about 6 times as high 
a risk to develop breast cancer as in the general population of young women [12,13]. They 
more often develop bilateral breast cancer and receptor negative tumors [12]. 
Family history 
Family history is a strong risk factor for women <40 years old. The risk is higher with an 
increasing number of first-degree relatives with breast or ovarian cancer and if the relatives 
are young at diagnosis [14]. If a woman <40 years old has one relative with breast cancer 
before age 40, her risk is almost 6-fold, decreasing to 2-fold if the relative is ≥60 years old at 
diagnosis [15]. A positive family history is present in almost 50% of the young women with 
breast cancer [16], but it is not a risk factor for worse survival [17]. 
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BRCA1/2 mutations  
In the general population, BRCA1/2 mutations are very rare. Only 0.2% of women are 
generally estimated to be BRCA1/2 mutation carriers. Translated into the Swedish female 
population of 4.9 million women (2016), this means that 9800 women can be estimated to 
be BRCA1/2 mutation carriers [18]. While the cumulative incidence of breast cancer for an 
unaffected 70-year-old woman is 10%, the risk is 6-fold (60%) for a BRCA1 mutation 
carrier of the same age. The cumulative incidence of breast cancer for a 40-year-old woman 
is generally 1%, while for a BRCA1 mutation carrier the corresponding risk is 20% (a 20-
fold increase) [6,19].  
Breast density 
Breast density is a strong independent risk factor for the development of breast cancer, and is 
associated with a 4-fold increased risk of the disease [20,21]. Breast density is a risk factor for 
breast cancer for women both <50 and ≥50 years old, according to a meta-analysis [21]. 
Breast density seems to be a proxy for a combination of genetic, hormonal and lifestyle risk 
factors predicting breast cancer. Breast density decreases with increasing age, but a woman 
with high breast density at age 40 will persist with a high baseline density throughout life, 
indicating that a high risk for breast cancer later in life can already be identified at a young 
age [22]. Dense breast tissue is over-represented in young women. In a study of 7000 
mammograms, 81% of the women <40 years old had dense breasts. The proportions for 
women aged 40-49, 50-59 and 60-69 years were 57%, 57% and 45%, respectively [23]. Dense 
breast tissue is related to both the risk of being young at the diagnosis of breast cancer, as well 
as the outcome of breast cancer, and thereby constitutes a classical confounder.  
Breast density is highly inheritable. Twin-studies have identified about 60% of dense breast 
to be ascribable to inherited genetic factors [24]. Breast density also carries a risk for breast 
cancer in women with BRCA mutations, as they have a higher proportion of high breast 
density than non-carriers [25,26].  
Reproductive factors 
In a large meta-analysis of risk factors for breast cancer in women aged 40–49 years, 
reproductive factors contributed only modestly with a 1.0 to 1.5-fold increased risk. The 
following reproductive factors were defined as risk factors: early menarche, age ≥30 years at 
first full-term pregnancy, <3 births or nullipara [14]. Breastfeeding and the duration thereof 
reduce the breast cancer risk in young women [5,14,27].  
 
Oral contraceptives increase the risk of breast cancer in young women. A lifetime use 
exceeding 15 years increases the risk 1.5-fold for women aged 20-44. Current use for 5 years 
or longer increases the risk for triple-negative (TN) breast cancer in women aged 20-39 
almost 4-fold [28]. In vitro fertilization does not increase the risk of breast cancer [29]. 
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Intrauterine exposure 
High birthweight (≥4 kg versus <3 kg) increases the risk of breast cancer 6-fold [30], with a 
stronger association for premenopausal presentation [31]. The mechanism is thought to be 
an oestrogen-mediated stimulation of mammary stem cells [32]. Also tall height at 8 years 
of age is associated with an increased risk of both premenopausal and postmenopausal 
breast cancer [31].  
Obesity 
Obesity increases the risk of postmenopausal breast cancer, but it is a protective factor for 
premenopausal women [33,34].  
Alcohol and smoking 
Alcohol and smoking are not risk factors for breast cancer in women aged 40-49 [14]. 
 
Diagnostic procedures in young women 
Clinical examination  
A palpable breast mass or lump in the breast is most often the first symptom of breast cancer 
in young women. The first presentation can also be nipple discharge or a lump in the axilla 
[35]. In a study on women <35 years old with breast cancer, only 37% of the cases yielded a 
strong suspicion of cancer at palpation, while another 20% were undeterminable and 43% 
were considered to be benign (most frequently with a fibroadenoma-like palpation finding) 
[36]. In a population-based study, 98% of the women <40 years of age were detected 
clinically [37]. 
Breast imaging  
Due to a higher proportion of patients with dense breast tissue among young women breast 
imaging is more difficult in young women than in older ones. In one study, the sensitivity of 
mammography was 30% in extremely dense breasts compared to 80% in predominantly fatty 
breasts [38]. Ultrasound has been shown to be superior as a first-line breast imaging 
technique up to age 45, correlating with a shift in the hormonal milieu by this age [39]. If 
ultrasound indicates a suspect malignancy (BI-RADS 3-5), the next step is a complementary 
mammography.  
MRI does not improve primary breast cancer diagnostics in normal-risk women (median 
ages, 50–63 years), but it increases mastectomy rates with more harm than good [40]. Nor 
does an MRI assessment in the primary investigation prevent future local recurrences [41] 
when assessed in women aged 49–64. MRI has been shown to be beneficial as a screening 
method in young women with a high risk of breast cancer [42], but it has not been 
determined whether or not it is beneficial in the primary breast cancer diagnostics of normal-
risk women <40 years old. In a small study on women <50 years old with breast cancer, MRI 
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did detect additional disease, leading to improved management in 44% of the cases, to no 
change in another 44%, and to excessively extensive surgery in 12% of cases [43]. A study on 
440 women <56 years old with breast cancer randomized to MRI or not resulted in a 11% 
lower breast reoperation rate in the MRI group, but no differences in the overall mastectomy 
rate between the groups were noted [44]. 
New diagnostic tools, such as Automated Breast Ultrasound (ABUS), can probably improve 
early diagnosis in young women as it is more sensitive in dense breast tissue than 
conventional mammography. The technique has a standardized protocol and can be 
performed by medical personnel and then interpreted afterwards by the radiologist. Adding 
ABUS to screening mammography increased the cancer detection rate by 37% in an 
American study [45] and by 57% in a Swedish study [46]. 
Cytology and histopathology 
The use of cytology and histopathology for confirmation as a part of the triple assessment is 
especially important in young women since both clinical examination and imaging have less 
sensitivity. Fine-needle aspiration has a high sensitivity (93–96%) in young women [36,47]. 
A histopathological confirmation to get information on tumor characteristics is important in 
young women as they have a large proportion of tumors that respond to neoadjuvant 
chemotherapy [48]. Knowledge of tumor characteristics at diagnosis is also important for 
raising the suspicion of the woman having a BRCA mutation, thereby gaining sufficient time 
for genetic testing before initiating radiotherapy. 
Screening  
Breast cancer screening is highly evidence-based and reduces breast cancer mortality by 25% 
when asymptomatic women aged 50–69 years are invited biannually [49]. As for younger 
women, several randomized trials from Sweden and the UK have shown the benefit of 
screening to be approximately 16% for women starting at age 40 with an interval between 
examinations of 12–18 months [50,51]. At long-term follow-up (24 years), the reduction of 
mortality increased to 40%, which is a larger reduction than in older women and can possibly 
be explained by a shorter screening interval in the younger age group [52].  
General screening for women <40 years old is not an option because of the low prevalence of 
breast cancer in this age group. Young women can be included in high-risk screening 
programs if they meet any of following criteria: a lifetime risk of breast cancer exceeding 20–
25%, being a carrier of a BRCA mutation, being a first-degree relative of someone carrying a 
BRCA mutation or having a history of chest radiation during ages 10–30. The screening 
modality for women <40 years old meeting these criteria is an annual MRI [42,53], whereas 
mammography does not seem to add any value in this context [54].  
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Tumor characteristics in young women  
Histological type 
Ductal carcinoma is the most common histological type in women <40 years old (nearly 90% 
of tumors) [37,55-58]. In women >60 years old, this proportion is about 70% [56]. Lobular 
carcinoma is uncommon in young women, but it increases in incidence with age (Table 1) 
[59]. A classic lobular carcinoma is ER+ (90%), PR+ (60-70%) and grade II with low Ki67 
[60], characteristics that are less common in young women. Generally speaking, medullary 
carcinoma is uncommon, but it is associated with young age, high grade, TN subtype [61] 
and BRCA1 mutation [62]. Histological type is associated with prognosis. On comparing 
histological type and the 21-gene recurrence score, tumors of the ductal type more often had 
a high-risk recurrence score, and those of the lobular type, a low-risk recurrence score [63]. 
Stage  
Young women are being diagnosed with breast cancer at more advanced stages, with both 
larger tumors and, more often, axillary lymph node involvement [64-68]. Young women are 
not included in screening programs. They have tumors with a higher proliferation rate and 
thus faster growth. Women with breast cancer aged <40 have a 3-fold higher risk of being 
diagnosed with high-stage disease [69]. Stage is one of the strongest prognostic indicators in 
breast cancer [70] and age-related differences in breast cancer survival have been shown to be 
present only in the early stages of disease. In the SEER dataset, age-related survival 
differences were studied in women diagnosed with breast cancer during 1988–2003 (n = 
240,012). The authors found a higher risk for women <40 years of age to die from breast 
cancer if they were in stages I and II [66]. In another registry-based study including women 
with breast cancer diagnosed during 2005–2009 (n = 59,191) and with a mean follow-up time 
of only 3 years, no age-related differences in prognosis by stage at diagnosis were identified 
[71].  
Nodal stage, or the number of involved axillary lymph nodes, has been known for decades as 
the most significant prognostic indicator in breast cancer [72,73]. Nodal stage is distributed 
differently across subtypes in young women: among those with luminal tumors, 44% had 
positive lymph nodes at diagnosis, with Her2+ tumors 65%, and with TN breast cancer only 
31% [55]. Basal-like tumors with a known inferior survival have a lower risk of being lymph 
node-positive at diagnosis, compared to luminal tumors (HR 0.5–0.6) [74]. Women with 
triple-negative, lymph node- negative breast cancer had a worse 10-year distant disease-free 
survival than those with Luminal A, node-positive disease (55% vs 88%) [75]. It seems that 
nodal stage remains prognostic in all subtypes. Nodal stage and subtype cannot replace one 
another as prognostic factors [76,77].  
Grade 
Grade is based on morphological features of the cancer cells, including scores on tubular 
formation, nuclear pleomorphism and mitotic count, summed up to grades I–III [78]. Young 
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women have a higher proportion of high-grade tumors than older women 
[55,57,64,66,68,71,79,80]. For women <40 years old, grade III versus grades I–II carry an 
independent risk for breast-cancer specific and overall survival [71], but not for local 
recurrence [80].  
 
Hormonal receptors 
The oestrogen receptor is expressed in several human tissues and over-expressed in breast 
cancer cells [81]. The presence or absence of ER in a tumor reflects rather the growth rate 
than the metastatic potential, and thereby rather the length of distant disease-free survival 
than overall survival [82]. ER is a strong predictor of the response to endocrine therapy [83-
85]. Compared to middle-aged and elderly women, young women generally have a lower 
protein and gene expression of ER [59,86,87]. In clinical practice, ER has been measured by 
means of immunohistochemistry (IHC) since the late 1990s, with a cut-off of 1% to define a 
positive expression [88]. The former cut-off of 10% was changed into 1% in 2010 [89], while 
publications suggest tumors with ER 1-9% compared to ER>10% have an inferior survival, 
less response to endocrine therapy and are more often seen in young women [90,91].  
 
Table 1. Tumor characteristics in women <35 and <40 years old at the diagnosis of breast 
cancer. The table is based on data from a literature overview including population-based 
studies and excluding duplicative publications based on the same cohort. Proportions are 
calculated on informative cases only.  
 
 Age <35 years Age <40 years 
 
% n/total Reference % n/total Reference 
Tumor <2 cm 51.9% 927/1786 55,57,79 48.5% 12020/12692 56-58,64,71 
Node neg 51.2% 922/1802 55,57,79 52.7% 14614/27717 56-58,64,71 
Grade III 57.5% 1109/1930 55,57,79 57.3% 6568/11462 3,57,80,56,64 
       
ER+ 77.1% 243/315 79 60.0% 12952/21592 3,5,56,57,58,80 
PR+ 67.9% 214/315 79 53.2% 2777/5220 3,5,56,57,80 
Her2+ 25.0% 282/1130 55,57,79 24.7% 1395/5651 3,5,56,57,80 
Ki67>20% 77.1% 239/310 79  no data available 
        
HR+Her2- 45.7% 1102/2410 55,71,79 50.1% 2191/4377 71 
HR+Her2+ 19.5% 471/2410 55,71,79 18.5% 811/4377 71 
HR-Her2+ 11.7% 281/2410 55,71,79 10.7% 469/4377 71 
TN 23.1% 556/2410 55,71,79 20.7% 906/4377 71 
       
Ductal 89.4% 1628/1821 55,57,79 87.6% 19354/22085 56-58,80 
Lobular 1.7% 31/1821 55,57,79 4.5% 984/22085 56-58,80 
LVI pos 43.1% 394/915 57,79 43.0% 2069/4811 57,64,80 
Multifocal 19.2% 158/825 55 29.7% 779/2624 80 
EIC pos no data available  20.3% 557/2746 80 
IHC, immunohistochemistry, ER estrogen receptor, PR progesterone receptor, HR hormonal receptor 
(ER/PR), TN triple negative, LVI lymphovascular invasion, EIC extensive in situ component 
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The progesterone receptor expression is induced by oestrogen signaling via ER [92]. PR is 
lower in postmenopausal women as oestrogen levels decrease after the menopause [93]. 
While ER is a strong predictor of endocrine therapy, the predictive role of PR has been more 
in dispute [94-96], and until recently, it has been considered a marker of ER function [97]. 
More recent data indicate that PR functions as a ‘proliferative brake’ in ER+ breast cancer 
[98]. ER+PR+ breast cancer is associated with a better outcome than ER+PR- tumors [99-
101]. PR is measured by IHC and a cut-off of 20% has been shown to be optimal [102].  
 
Her2 
Human epidermal growth factor receptor 2 is a gene coding for a signalling network 
controlling cellular proliferation, apoptosis, tumor cell motility and capacity for metastatic 
dissemination [103]. Amplification of the gene produces correspondingly high Her2 protein 
levels, which are seen in about 15-20% of women with primary breast cancer and which 
correlates with a worse survival [104]. Her2-positivity is 1.5-2 times as common in young 
women [3,5,57,71,77,79,105,106]. Her2 is analysed by IHC and the amount of Her2 
receptor protein on the cancer cell surface gives a score of 0 to 3+. If the score is 0 to 1+, it is 
considered negative, while a score of 2+ is equivocal and a score of 3+ is positive. For 
equivocal cases, a confirmatory analysis is done using an in situ hybridization method that 
detects amplification of the Her2 gene [107]. A Swedish national survey of the 
reproducibility of Her2 analyses using IHC and FISH showed high quality and 
reproducibility using TMA-based samples [108]. 
 
Proliferation  
Proliferation is a hallmark of cancer [109] and is prognostic in most cancer types. 
Proliferation markers are highly expressed in young women with breast cancer regardless of 
whether they are estimated by gene expression [59,110], grade [3,57,67,105], Ki-67 
[79,111,112] or cyclins [113-117]. In clinical treatment decision-making for women with 
luminal (Her2-negative) breast cancer, proliferation is heavily relied on, and is most often 
measured by Ki-67 when gene-expression analyses are not available [48].  
Ki-67 is a protein expressed during the whole cell cycle, except in G0 [118]. In clinical 
practice, it is used to separate Luminal A from Luminal B subtype [48]. In order to find an 
IHC substitute for the molecular intrinsic subtypes, Cheang et al. compared gene expression-
based subtypes with IHC and found a Ki-67 level of 14% to best define the cut-off between 
the Luminal A and Luminal B subtypes [119]. The best Ki-67 cut-off is still the subject of a 
major debate worldwide. According to the latest St Gallen Guidelines, a Ki-67 of 20–29% 
should be interpreted by local laboratory references, while a value of <10% is definitely 
considered low and >30% high [48]. 
Cyclins are a family of proteins that regulate cellular growth and division in both normal and 
malignant cells [120]. The regulation is mediated by cyclin-dependent kinases [121]. Cyclins 
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display subtype-specific expression in breast cancer [122-125] and are generally expressed in 
higher levels in young women [114-117,126]. 
Lymphovascular invasion 
LVI is overrepresented in young women [57,64,127,128] (Table 1). LVI is a strong 
independent marker of a worse breast cancer-specific survival [129,130] and locoregional 
recurrence in young women [131,132]. LVI has also been shown to be predictive of the 
response to neoadjuvant chemotherapy [133], but, in treatment decisions, it is not in and of 
itself considered to be sufficient to move patients from a low-risk group to a high-risk group 
[134].  
Subtype  
When analysed with microarray-based gene expression, breast cancer comprises a 
heterogeneous group of tumors with different distinct molecular features. The intrinsic 
molecular subtypes were originally described by Perou and Sorlie et al. in year 2000 [135]. 
Based on hierarchical clustering on fresh-frozen tumor material, they identified four distinct 
subtypes with distinct gene expression patterns: Luminal, Her2-enriched, Basal-like and 
normal-breast-like. Subsequent studies led to the Luminal subtype being divided into two, 
Luminal A and Luminal B [136], and to additional molecular subtypes being found, 
including the claudin-low [137,138] and the molecular apocrine subtypes [139].  
Molecular subtypes have later been translated into corresponding IHC subtypes (Figure 2), 
which is not a perfect match [138], but still provides a good estimation of prognosis 
[140,141]. When using IHC-based subtypes the biggest challenge is to separate Luminal A 
from Luminal B since they have divergent prognoses and treatments. Tumors expressing 
ER+PR-Her2- have a worse prognosis than ER+PR+Her2- tumors and are thereby 
considered to be a Luminal B subtype, no matter what level of Ki-67 is [142-144].  
Figure 2. Subtypes 
with IHC 
according to St 
Gallen Guidelines 
2015.  
 
The Luminal A subtype is twice as common in older women as in younger ones 
[3,56,57,77,79,105,145]. Almost 50% of young women have a luminal breast cancer, and a 
All#tumors#
ER+# ER-#
Her2+#Her2-# Her2+# Her2-#
PR+# PR-#
Lum#B#Lum#A# TN#Her2+#Lum#Her2+#
Ki-67+#Ki-67-#
PR+# PR-#
Un-#
classiﬁed#
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large proportion of them have high proliferation and high grade. Only a small proportion of 
tumors in the young will be of the Luminal A subtype when subtyping is based on IHC 
(Table 1). Luminal A is associated with the best survival of all subtypes in both young and 
older women [56,71]. In a study on prognosis in a large American population database, 
young age constituted an independent risk for breast cancer death in Luminal A disease (in 
this study, defined by ER+/PR+ and grade I-II) [3]. 
The proportion of luminal tumors of the Luminal B type is higher in young women than in 
older women [57,105]. Young women with tumors of the Luminal B subtype have a worse 
survival compared to older women [105,146,147]. In the gene-derived intrinsic molecular 
subtypes, the Luminal B subtype includes approximately 30% Her2+ tumors [112,119,148]. 
These Luminal Her2+ tumors are distinctively different from Luminal Her2- tumors since 
they can receive targeted therapy with trastuzumab and they should not be inappropriately 
classified as Luminal B [119]. 
The Her2+ subtypes are 1.5–2 times more frequent in young women than in older women 
[56,57,79,105,149]. The prognosis is similar for both young and older women [79,105,150]. 
TN breast cancer is twice as frequent in young women as in older ones [3,5,56,57,77,79,105]. 
There are no age-related differences in the prognosis within the TN subtype [151,152].  
Tumors expressing ER-PR+Her2- have not been considered to belong to a separate 
reproducible subtype [95,153,154] although evidence for the opposite has also been 
published [155]. If they do indeed exist, ER-PR+Her2- tumors are uncommon and 
represent between 1% and 4% of all tumors [77,155] and are somewhat more common in 
young women [156].  
BRCA associated breast cancer  
In a Swedish study on unselected women with breast cancer, the prevalence of BRCA 
mutations was only 0.4% [157]. Since BRCA-associated breast cancer penetrates at a low age, 
the prevalence in young women is much higher. In a Swedish population-based study, 9% of 
the women <41 years old at diagnosis had a BRCA1/2 mutation [16]. In a prospectively 
collected American cohort where the indication for testing was breast cancer at age <40 years, 
the prevalence of BRCA1/2 was 12.4% [158]. In an unselected breast cancer population, 
12.2% of the women ≤45 years old tested positive for the BRCA1/2 mutation [159]. In a large 
population of women subjected to genetic testing (n = 35,000), 14.4% of those <40 years old 
had a pathogenic variant of one of the 25 most common inherited breast cancer genes (in 
women aged <40, approximately 65% had BRCA mutations) [160]. In the subgroup of 
women with TN breast cancer, the corresponding prevalence was 24.8%. BRCA1/2-
associated breast cancers are more often of the TN subtype and grade III [159]. All women 
with breast cancer <40 years of age should be recommended testing for BRCA mutations 
[161]. 
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Treatment 
Breast surgery 
The proportion of young women having a mastectomy is higher (45-50%) than in older 
women (35%) [37,55]. Breast-conserving surgery (BCS) in women <40 years old is associated 
with a somewhat higher risk of local recurrence (LR) than mastectomy, but the type of 
surgery does not affect either distant disease-free survival or overall survival [80,162,163]. 
Multifocal lesions and extensive DCIS are more frequent in young women [55,80], which 
can affect re-excision rates, which are known to be higher in young women due to both 
tumor biology and smaller breast volumes [164]. It is of extra concern to have free margins 
after BCS in young women. Invasive cancer cells present on inked margins increased the LR 
rate 4-fold in women <40 years old, but not in women >40 years old [165]. Women operated 
on with BCS have a better quality of life than those who had a mastectomy and, with the 
long life expectancy of young women with breast cancer, BCS should be the first option 
whenever suitable [166]. In a cohort study of 965 women<40 years old, the 15-year outcomes 
concerning LR, distant metastases, breast cancer survival and overall survival were similar 
between those operated on with mastectomy and those operated on with BCS followed by 
whole breast radiotherapy [167]. 
Immediate breast reconstruction is safe in young women and should be offered to all women 
having the indication for mastectomy. Relative contraindications are locally advanced breast 
cancer involving skin or thoracic wall at diagnosis, grave psychiatric disease, smoking and a 
high BMI. Inflammatory breast cancer is an absolute contraindication [168]. Planned 
postmastectomy radiation therapy influences the cosmetic outcome after implant-based 
reconstruction, but most often, it still gives satisfactory results [169]. A systematic review has 
concluded that implant reconstruction should be advised prior to radiotherapy, while it is 
slightly better to perform autologous reconstruction after radiotherapy [170].  
Axillary surgery 
Approximately 50% of women <40 years old with breast cancer have lymph node-positive 
disease at diagnosis [5,55,64,66,80], compared to 70% at ages >40 [5,56,58,66], thus 
corresponding to a larger proportion of young women being operated on with an axillary 
clearance. The prevalence of lymphoedema at 5 years after surgery is high in young women 
(32%), and two of the risk factors for persistent swelling of the arm are the number of axillary 
nodes removed and obesity [171].  
Axillary management is in the process of changing towards less extensive surgery, and this 
will benefit young women with breast cancer. For women with a maximum of 2 macro-
metastatic lymph nodes, it is now considered safe to avoid axillary dissection [172]. However, 
it is worth noting that, for women <40 years old, the probability of axillary recurrence is twice 
as high as in older women [57,173]. 
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Chemotherapy 
Due to stage and subtype distribution, young women often have indications for 
chemotherapy. Since the year 2000, chemotherapy has been given to more than 90% of 
women <35 years old with breast cancer [55,80].  
In the 1995 St Gallen Guidelines, age <35 was defined as high risk, and thereby, in and of 
itself, an indication for chemotherapy, no matter the stage or tumor biology [174]. This was 
further strengthened by Kroman et al. in 2000 in a randomized study on CMF versus no 
systemic treatment showing that women <35 years old have a 2.2–fold relative risk of dying 
compared to women aged 45–49 in the non-systemic treatment arm, whereas no difference in 
survival was seen within the chemotherapy arm [2]. In the 2005 St Gallen Guidelines, age 
<35 was lowered to an intermediate risk, resulting in chemotherapy being optional in young 
women with endocrine responsive tumors [175]. In the guidelines from 2009, age itself was 
no longer a reason for chemotherapy [176]. In clinical practice, there has been a major change 
in the use of chemotherapy during the last few decades, regarding both the proportion of 
patients treated and indications for treatment, as well as the choice of regimens. In a 
population-based Dutch study [177], 90% of the chemotherapy-treated women in the year 
2000 received cyclophosphamide, methotrexate and 5-fluorouracil (CMF), while almost 
none were given CMF in 2005. In 2005, 96% of the treated women were assigned to 
anthracyclin-containing regimens, which gradually decreased to 68% in 2008 when, instead, 
taxane-containing regimens became more common, increasing from 24% to 34% between 
2005 and 2008. 
Neoadjuvant chemotherapy has developed from being an option for inoperable, locally 
advanced disease, to being the first option in tumors measuring 3 cm or larger, in case of node 
involvement, or in case of Her2+ disease. Neoadjuvant chemotherapy offers a biology-based 
treatment with the possibility of evaluating treatment response, increasing the chances of 
successful BCS and obtaining the surrogate prognostic information concerning a pathological 
complete response (pCR). In a population-based cohort of women diagnosed in 2000-2008, 
chemotherapy was given neoadjuvantly to 15.5% of the women <40 years old [80]. 
Nationwide population data from Sweden in 2014 showed that neoadjuvant chemotherapy 
was used in 19% of women of all ages and, in some regions, in up to 26% of women with 
primary breast cancer [178]. 
Women <40 years old have a higher rate of pCR than older women, especially for luminal-
Her2-negative breast cancer [179]. Neoadjuvant studies have facilitated the introduction of 
more modern chemotherapy regimens such as docetaxel, adriamycin and cyclophosphamide 
(TAC). The highest pCR rates after TAC treatment have been observed in women <40 years 
old with TN or grade III tumors [180]. Neoadjuvant studies on women with TN breast 
cancer carrying BRCA1/2 mutations have been shown to be promising, with high pCR rates 
when platinum salts have been added to standard chemotherapy [181].  
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Endocrine therapy 
Today it is beyond all doubt that all women with ER+ breast cancer should be treated with 
endocrine therapy [94,182]. In 1992, the recommendation for premenopausal women with 
low risk (node-negative tumors <1 cm found incidentally) was observation or tamoxifen, for 
intermediate risk (node-negative, tumors 1–2 cm), tamoxifen and for high-risk ER+ tumors, 
chemotherapy +/- tamoxifen and, for high risk ER- tumors, chemotherapy only [183].  
The options for endocrine treatment available today are tamoxifen, aromatase inhibitors (AIs) 
and a combination of either one of them with gonadotropin-releasing hormone (GnRH) 
agonists for ovarian function suppression (OFS). The standard endocrine treatment 
recommendation for premenopausal women with luminal tumors is tamoxifen for 10 years. 
According to the EBCTCG meta-analysis, 5 years of tamoxifen reduces the risk of 
recurrence by 50% throughout the first 10 years, independently of age, PR status, nodal stage 
and use of chemotherapy [94] and also reduces the 15-year mortality by a third. Extended 
adjuvant endocrine therapy with prolonged tamoxifen has been proved to be efficient in two 
very large trials [184].  
For high-risk women (<35 years old or still premenopausal after chemotherapy or multiple 
axillary metastases), the recommendation is tamoxifen or AI for 10 years in combination with 
OFS for 2 years [48]. In the randomized SOFT and TEXT trials, premenopausal women 
given endocrine treatment including 3 years of GnRH, had a superior disease-free survival 
but no survival benefit [185,186].  
Resistance to endocrine therapy may be more common in young women. They have a 
higher proportion of the Luminal B subtype that confers less benefit from endocrine 
therapy compared to those with Luminal A subtype [187]. In women with ER+ tumors, 
given both chemotherapy and endocrine therapy, women aged 35–50 had a survival benefit 
not seen in women <35 years old [188]. In a Swedish trial, premenopausal women with ER+ 
tumors benefitted from adjuvant tamoxifen only when PR was >75% [189]. Young women 
are less compliant with endocrine therapy than older ones [190-192]. 
 
Anti-Her2 treatment 
Trastuzumab, a monoclonal antibody against Her2, was introduced in Europe in the year 
2000 and in the adjuvant setting in 2005 [193]. In a Dutch study on women <35 years old, 
trastuzumab was introduced as a part of treatment in 2005, with successively increasing use 
towards 2008 [55]. Anti-Her2 treatment should be offered to all patients with Her2+ tumors, 
without taking age or menopausal status into account [150]. International guidelines 
recommend that all women with Her2+ breast cancer should receive 1 year of trastuzumab, 
except in very small (≤5 mm) node-negative tumors where trastuzumab can be omitted [48]. 
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Radiotherapy 
Young women with breast cancer have a high risk of local recurrence (LR) which is ascribed 
to their higher proportion of characteristics associated with an increased risk of LR (Table 1). 
In addition to the ordinary dose of 50 Gy to the breast, young women are recommended an 
extra boost of 16 Gy to the tumor bed after BCS [194]. Boost decreases the 10-year LR rate 
in young women by 50%, but has no effect on survival. [195]. Tumors of the Her2+ subtypes, 
which are more common in the young women, may be associated with resistance to 
radiotherapy and thus a higher risk of LR [196].  
 
Risk prediction models 
 
Different tools have been developed to tailor the treatment decision and select women in 
need of chemotherapy and/or endocrine therapy. The clinical risk can be measured as follows: 
The Nottingham Prognostic Index (NPI) [197,198](1982) uses tumor size, grade and lymph 
node status in an equation to indicate excellent, moderate and poor prognostic groups. 
Adjuvant online! [199,200](2001) is an online tool using age, tumor size, number of positive 
axillary nodes, grade and ER status to provide an estimate of the 10-year outcome.  
PREDICT [201-203](2010) is another online tool using age, mode of detection, tumor size, 
lymph node status, grade, ER, Her2, Ki-67 status and given treatment for prediction of 
prognosis.  
 
Risk prediction models are generally well validated, but not for women <40 or >70 years old. 
Adjuvant online! has been shown to underestimate the risk of recurrence in up to 30% of 
women <40 years old [204]. PREDICT provides an accurate 10-year survival rate for women 
<40 years old, but the 5-year survival was overestimated for ER+ tumors and underestimated 
for ER- tumors [205]. 
The genetic risk can be measured by gene expression profiling (GEP) with the aim of 
improving decision-making regarding adjuvant chemotherapy in early breast cancer. 
Various commercial assays stemming from a common base of multiple genes expressing 
ER, Her2 and proliferation are available. Fresh-frozen tumor material or FFPE can be used 
with either deoxyribonucleic acid (DNA) microarrays or the reverse transcription-
polymerase chain reaction (RT-PCR). 
MammaPrint [206-208](2002) is a microarray-based assay of 70 genes allocating patients 
with early node-negative or node-positive breast cancer and endocrine treatment to a high-
risk group (with additional benefit from chemotherapy) or a low-risk group (with no 
statistically significant additional benefit from chemotherapy). 
Oncotype DX [110,209](2004) is an RT-PCR analysis based on 21 genes. It is used to 
predict the benefit of chemotherapy, as well as the likelihood of distant disease at 10 years 
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in women with ER+ early breast cancer. The Oncotype DX Recurrence Score is a score 
between 0 and 100 reflecting a successively higher risk of distant disease in both node-
negative and node-positive disease. The Oncotype DX assay has mainly been validated in 
ER+, node-negative disease in patients with a median age of 50–60 years. 
MapQuant DX [210](2006) uses 8 genes to produce a Genomic Grade Index that improves 
the histological grade classifications and divides histological grade II tumors into either 
grade I or grade III. 
The PAM50 [211](2009) assay is a minimal gene set based on 55 genes for classifying 
intrinsic-like subtypes of breast cancer. It produces a continuous risk score and also 
determines the benefit of chemotherapy in addition to endocrine therapy in 
postmenopausal women with ER+Her2-negative breast cancer. The evidence is mostly 
based on node-positive patients, and only one study included premenopausal patients. 
 
Local recurrence  
 
Young age is an independent risk factor for LR, after both breast-conserving surgery and 
mastectomy [196,212-217]. The risk of having an LR due to young age is twice as high as 
that in middle-aged women [212,218]. The younger the patient, the higher the risk of LR. 
The risk for women aged <35 is higher than for women aged 35–39 [215]. The risk of LR 
in women <40 years old was 3.4% after 5 years and, in women >40 years old, 1.6% [196]. 
Established risk factors for LR are late stage diagnosis, high grade, subtype distribution, 
dense breast tissue [219], LVI, multifocality and the presence of extensive DCIS [218]. All 
of these characteristics are common in young women (Table 1). The subtypes associated 
with the highest risk of LR in young women are the Her2+ and TN subtypes [55,196,220].  
Owing to a more biology-influenced approach in treatment decisions, the introduction of 
trastuzumab and taxanes, improvements in diagnostics and radiotherapy, the incidence of 
LR has decreased substantially over time and is now well under 1% per year also for the 
youngest women [55,221].  
 
Distant recurrence and mortality 
Young age is an independent risk factor for distant recurrence [57,216], but it seems to be 
restricted to early stages of the disease and to the luminal subtypes [3,79,147,152,188,222]. 
The majority of recurrences in young women are distant, not local. Among women <40 years 
old, 4.8% had an LR, versus 26.1% with a distant recurrence, at a median follow-up of 7 years 
[80]. In line with the observed decrease in LR with more modern systemic therapy, the 
incidence of distant recurrence has also decreased in young women. In 2003, women <35 
years old had a 5-year distant recurrence rate of 17.8%. From 2004 to 2008, the 
corresponding rates were 19.2%, 14.6%, 8.2%, 8.1% and 10.0%, respectively [55].  
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There are no age-specific patterns of metastatic behaviour. Subtype-specific trends show a 
low frequency of metastases in women after Luminal A tumors. The metastases that occur 
are mostly bone metastases associated with a favourable prognosis. Her2+ and TN breast 
cancer have the highest risk of distant metastases, often visceral metastases occurring during 
the first three years [223,224].  
 
Contralateral breast cancer 
Young age at breast cancer diagnosis entails a risk for a later (metachronous) contralateral 
breast cancer (CBC) together with a BRCA mutation, positive family history, high breast 
density, lobular breast cancer, TN breast cancer, large tumor size and positive axillary lymph 
nodes [225-228]. The cumulative risk of CBC at 10 years is 4% for a 60-year-old woman and 
6% for a 40-year-old woman, with a decreasing trend with modern systemic therapies 
[225,226]. Endocrine therapy decreases the risk of CBC by 50% [83]. Not only invasive 
breast cancer but also DCIS increases the risk of CBC. In a Swedish population-based study 
especially women aged <40 were at risk of a new contralateral event [229]. The majority of 
young women affected with primary unilateral breast cancer overestimate their risk of CBC. 
The risk of CBC is, in fact, similar (0.7% per year) [226] to the risk of a LR at the primary 
site (0.6% per year) [196]. Still, the risk of having distant metastases is much higher (2.8% per 
year) [55]. A study on the chromosomal relationship between the primary tumor and the 
CBC showed 1 in 10 CBC to be rather a distant spread instead of a new primary one [230]. 
Bilateral breast cancer at presentation (synchronous) is uncommon (fewer than 2%) and 
associated with older age [226,228]. Prophylactic mastectomy decreases the risk of CBC, but 
with no evidence of improved survival [231]. 
 
Fertility and pregnancy 
Chemotherapy and endocrine therapy-induced amenorrhoea is common in young women 
[232]. The treatment’s effects on fertility must be discussed with the young patient as soon as 
possible after the diagnosis. Early referral to a fertility clinic is strongly advised to discuss 
methods of fertility preservation. The available options for fertility preservation are ovarian 
stimulation with letrozole (AI), followed by egg retrieval for cryopreservation or in vitro 
fertilization for embryo cryopreservation. A third option is ovarian tissue harvesting and 
cryopreservation for later re-implantation [233].  
Whether or not the use of GnRH agonists during chemotherapy preserve ovarian function 
has been investigated in several studies. According to two recent meta-analyses, GnRH 
appears to improve ovarian function and the ability to achieve pregnancy following 
chemotherapy [234,235]. 
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Pregnancy-associated breast cancer (PABC) is defined as breast cancer detected during 
pregnancy or within one or two years since delivery. Every 4th breast cancer patient <35 years 
old and every 10th before age 40 is diagnosed during pregnancy. The incidence is increasing as 
women are postponing childbirth to later in life [236]. Women with PABC are more often 
diagnosed in advanced stages. Compared to other young women characterized by comparable 
age, stage and tumor biology, the prognosis does not differ [237,238].  
Breast cancer treatment during pregnancy should not be inferior to that in the non-pregnant 
setting to spare the child [239]. The indications for breast surgery are the same as for non-
pregnant women, but a sentinel node biopsy without blue dye is recommended. Endocrine 
therapy [240], trastuzumab [241] and radiotherapy [239] are contraindicated, whereas 
chemotherapy during the second and third trimester is well tolerated with no detrimental 
effect on the foetus. During the first trimester, chemotherapy is contraindicated due to a 
relatively high risk of congenital malformations. Women with breast cancer during pregnancy 
should be managed within a multidisciplinary team also including an obstetrician and a 
neonatologist. Delivery is recommended at full term after gestational week 37 [242]. 
Pregnancy after breast cancer does not impair the long-term prognosis, but rather has a 
protective effect on survival [243,244]. The best timing of pregnancy after ER+ breast cancer 
has not yet been established. There is an ongoing prospective study on women <42 years 
with ER+ breast cancer and a pregnancy desire (called POSITIVE) [245]. After 18–30 
months of endocrine therapy, the treatment is interrupted for up to two years to enable a 
pregnancy. 
 
Quality of Life 
For everyone diagnosed with cancer, the diagnosis will have a huge impact on their daily life 
with physical, emotional, social and existential concerns. Young women with breast cancer 
have a worse Quality of Life (QoL) than middle-aged and older women, and the duration of 
reduced QoL is longer [246,247]. The QoL is even worse for young women affected by 
breast cancer than by other cancers [248] and a possible explanation could be that breast 
cancer treatment has a large impact on body image and sexual functioning and entails a 
premature menopause. Women with children and women with earlier psychiatric illness have 
a lower QoL [248]. To improve their QoL, young women with breast cancer should be 
offered interventions specifically designed to target their specific needs [166]. 
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AIMS OF THE THESIS 
 
The general aim of the thesis was to gain increased insight into the long-term prognosis for 
young women with breast cancer. 
 
More specifically, the aims were to: 
 
• study the long-term outcome by age for women diagnosed with breast cancer and 
to investigate the extent to which a worse prognosis for women aged <35 can be 
explained by stage, tumor characteristics, heredity, parity and treatment 
 
• gain further insight into the biology behind the age-related differences in the 
prognosis for breast cancer 
 
• find new prognostic markers that can help us to determine which of the young 
women that have an excess risk of recurrence 
 
• assess the expression of proliferation markers in relation to age and subtype in 
order to clarify whether cyclins add prognostic information to the standard 
biomarkers in young women 
 
• to compare Her2-status generated by testing Her2 gene copy numbers (with silver 
in situ hybridization) and by Her2 protein expression (using 
immunohistochemistry) in a population-based cohort with a long-term follow-up 
and to find out whether either test method is superior for predicting the prognosis 
in young women who have a known overrepresentation of Her2-positive breast 
cancer. 
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PATIENTS AND METHODS 
 
Studies I–IV are based on the same cohort identified from the regional Breast Cancer Quality 
Registries in Stockholm-Gotland and Uppsala-Örebro. We used the Swedish Personal 
Identification Numbers (PIN), assigned to all Swedish residents, for linkage between all 
registers used [249].  
 
Data sources 
The National Breast Cancer Quality Registry 
The National Registry is based on joint information from the 6 different regional breast 
cancer quality registries in Sweden. It is updated continuously by matching with the Total 
Population Register, The Swedish Cancer Registry and The Swedish Causes of Death 
Registry. The National Registry contains prospectively collected data on patient, tumor and 
treatment characteristics and has a high validity. Since 2008, this registry has been organized 
on a web-based platform, INCA. In 2015, the coverage was 97% [178]. In the two regions 
from which data for our study cohort were taken, the Stockholm-Gotland and the Uppsala-
Örebro regions, the Breast Cancer Quality Registries were started in 1976 and 1992, 
respectively. These two regions cover about 43% of the Swedish population [18]. 
The Swedish Cancer Registry 
The Swedish Cancer Registry, located at the National Board of Health and Welfare, was 
established in 1958 and includes data on all diagnosed malignant (and some benign) primary 
tumors in Sweden. Reporting to this registry is mandatory by law, and since both the 
handling clinician and pathologist are each required to make the report, the coverage is very 
high, being >98% for breast cancer [250,251]. Individuals are identified by their PIN and 
tumors are coded with the International Classification of Disease (ICD) code. This registry 
includes data on the tumor site and histology, as well as dates, diagnostic methods and the 
name of the hospital providing the diagnosis. 
The Swedish Causes of Death Registry 
This nationwide registry, also located at the National Board of Health and Welfare, collects 
information on causes of death of Swedish residents who die in Sweden or abroad. This 
registry was initiated in 1751, digitalized in 1952, and its completeness is >99% [9]. This 
registry includes data on date of death, place of residence, underlying cause of death and 
contributing causes of death. Individuals are identified by their PIN and the cause of death 
coded with the ICD code. 
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The Total Population Registry 
This registry held by Statistics Sweden contains civil registration information on all private 
individuals in Sweden including PIN, sex, births, marriage and partnership, address, country 
of birth and assessed personal income tax [252]. Information on migration in and out of 
Sweden is available in the registry. 
 
Study population 
For the purpose of this thesis, all women aged 20–69 diagnosed during 1992–2005 with a 
primary invasive breast cancer (unilateral or synchronous bilateral) in the Stockholm-Gotland 
and Uppsala-Örebro regions were identified from the regional Breast Cancer Quality 
Registers. These women were included in the study cohort from which all studies (I–IV) in 
this thesis were derived (Figure 3).  
Figure 3. Flow-
chart of Studies I-
IV. 
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Exclusion criteria were earlier breast cancer (n=617) and less than a one-month follow-up 
(n=52). In case of synchronous bilateral disease (n=260, 1.2%) the one in the most advanced 
stage was chosen as the index tumor. After exclusions, the cohort (Study I) consisted of 
22,017 women, with 11,527 women from the Stockholm-Gotland region and 10,490 from 
the Uppsala-Örebro region. Women in the cohort were divided into four age groups: 20–34 
(n = 471), 35–39 (n = 858), 40–49 (n = 4789) and 50–69 years (n = 15,899). 
In Study II, registry data were supplemented with information from medical records and 
analyses of tumor tissue. All women <35 years old at diagnosis (n=471) from Study I were 
compared to randomly sampled groups of women aged 35–39 (n=200), 40–49 (n=200) and 
50–69 (n=300) from the same cohort (Figure 3). The size of the sample was decided after a 
power calculation based on effect sizes from Study I, with the aim to over-sample young 
women aged 35 or older, but still with a reasonable possibility of collecting detailed clinical 
data and tumor tissue for cases and the comparison group. To reach a power of 80% at a 95% 
significance level, we needed 326 individuals to detect a difference in breast cancer-specific 
survival and 262 individuals to detect a difference in locoregional recurrence-free survival. 
After exclusions (3 wrongly registered as having breast cancer, 10 with DCIS, but wrongly 
registered as having invasive breast cancer), the new smaller cohort, still with its population-
based origin, consisted of 1171 women (Table 2). 
 
Women with DCIS are also included in the Breast Cancer Quality Register but were not 
selected for this cohort. In our sample of the cohort, we found the accuracy of registration to 
be 99.7% (1168/1171). As survival was the main outcome, we restricted further analyses to 
stage I–III disease, leaving out 38 women with stage IV disease at diagnosis. The final study 
base for Study II consisted of 1120 women. Stage IV was defined as the presence of a distant 
metastasis at diagnosis or within three months of the diagnosis. TNM staging was done 
according to UICC criteria [253]. 
Table 2. Comparison of cohort in Study I and II. 
	  
   Study I Study II 
  
Study I Study II 
Age distribution n (%) n (%) 
 
Region/County n (%) n (%) 
20-34 years 471 (2,1) 471 (40) 
 
Sthlm+Gotland 11,527 (52) 662 (57) 
35-39 years 858 (3,9) 200 (17) 
 
Uppsala/Örebro 10,490 (48) 509 (43) 
40-49 years 4789 (21,8) 200 (17) 
 
     Uppsala 1545 (7) 80 (7) 
50-69 years 15,899 (72,2) 300 (26) 
 
     Södermanland 1525 (7) 67 (6) 
total 22,017 (100) 1171 (100) 
 
     Värmland 1648 (7,5) 75 (6) 
Median age years years 
 
     Örebro 1425 (6,5) 78 (7) 
20-34 years 31 31 
 
     Västmanland 1420 (6) 61 (5) 
35-69 years 55 49 
 
     Dalarna 1457 (7) 86 (7) 
   
 
     Gävleborg 1470 (7) 62 (5) 
35-39 years 37 37 
    40-49 years 45 45 
    50-69 years 59 59 
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In Study III, we related the expression of proliferation markers to subtype and age. All 
women from Study II with information on subtype were included in Study III (n=887).  
In Study IV, we investigated whether or not added information on Her2 by SISH could 
explain survival differences between young and older women. All women from Study II 
included in TMA (n=983) except those without information on Her2 obtained either by 
using Silver in Situ Hybridization (SISH) or IHC (n=154) were included, leaving 829 women 
in the cohort. 
Methods 
Clinical data (Studies I-IV) 
For Study I, the two regional Breast Cancer Quality Registers in Stockholm-Gotland and 
Uppsala-Örebro regions were combined into one large dataset. The registers contained 
slightly different variables, but most variables were joined and merged into one dataset (Table 
3). Missing data were presented and there was no use of imputation. Data in the registers on 
multifocality, grade, ER and PR were incomplete to such an extent that they were deemed 
unreliable.  
In Study II detailed clinical information was collected from medical records after ethical 
approval and local permission from supervisors at all involved clinics. New data were collected 
blinded from the individual data retrieved from Study I, as presented in Table 3.  
Table 3. Variables collected for Studies I-IV. 
 
Study&I&
&
&
&
&
Study&II&
&
&
&
&
&
&
&
&
&
&
Study&III&
&
Study&IV&
&
Registry&
Age,%county%of%residency,%date%of%diagnosis,%menopause%status,%mode%of%detec4on,%contralateral%
breast%cancer,%mul4focality,%tumor%side,%tumor%size,%number%of%lymph%nodes%examined,%number%
of%posi4ve%lymph%nodes,%TNM>stage,%grade,%ER,%PR,%treatment%(inten4on%to%treat%data);%type%of%
breast%and%axillary%surgery,%radiotherapy,%chemotherapy,%endocrine%therapy%
Medical&records&
Age,%length,%weight,%parity,%pregnancy%associa4on,%heredity,%mode%of%detec4on,%tumor%size,%
lymph%node%status,%grade,%ER,%PR,%prolifera4on,%Her2,%EIC,%mul4focality,%LVI,%histological%type.%
Given%treatment;%type%of%breast%and%axillary%surgery,%surgical%margins,%re>excisions,%profylac4c%
surgery.%Type%and%length%of%chemotherapy,%endocrine%therapy%and%radiotherapy.%Treatment%of%
LR.%Date%and%loca4on%of%contralateral%breast%cancer,%LR,%distant%recurrence.%Date%and%cause%of%
death,%last%day%of%follow>up.%%
Pathology&review&
Grade,%LVI,%lymphocyte%inﬁltra4on,%cancer%in%situ%component,%tumor%invasion%front%
TMA&&
ER,%PR,%Ki>67,%Her2%(IHC,%for%2+%conﬁrma4on%of%Her2%gene%by%SISH),%EGFR,%CK%5/6,%14,%17%
TMA&&
ER,%PR,%Ki>67,%Her2,%Her2%SISH,%CK%5/6%
TMA&&
ER,%PR,%Ki>67,%Her2,%Cyclin%A2,%cyclin%B1,%cyclin%D1,%cyclin%E1%
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EIC and multifocality were extracted from the pathology reports. EIC was defined as >25% 
of the tumor consisting of DCIS with an intraductal component also beyond the edge of the 
invasive tumor. Multifocality was defined as two or more invasive tumor foci separated by at 
least 1 cm. For the 8 women lost to follow-up, the cause and date of death was retrieved from 
the Swedish Causes of Death Register. After data collection was completed, all of the 
included study subjects were anonymized, leaving only their given specific study code. The 
code key was kept separately. The cohort was recorded as a research registry according to the 
Swedish Data Protection Authority [254]. Clinical data retrieved for Study II was also used 
for Studies III and IV. 
 
Tumor tissue (Studies II-IV) 
To retrieve tumor tissue, permissions from the 11 pathology departments involved were 
obtained according to the Law on Biobank for Research Purposes [255]. The collected tumor 
tissue was gathered in a sample collection at the Karolinska University Hospital Biobank.  
When available, original haematoxylin and eosin stained sections were retrieved; otherwise, a 
re-sectioning and re-staining was preformed. The pathologist reviewed sections for grade 
according to Elston and Ellis [78], LVI, lymphocyte infiltration, cancer in situ component 
and tumor invasion front.  
The pathologist marked tumor-representative areas on the section and tissue microarrays 
(TMAs) were generated from 1.0-mm cores in duplicate from each patient’s archival FFPE 
tumor block. From the TMA blocks, 4 µm sections were cut and automated IHC was done 
using a Lab Vision Autostainer 480 (Thermo Fisher Scientific).  
The IHC stained and mounted TMA sections, as well as whole tumor sections, were scanned 
at 20x magnification using a ScanScope XT System (Aperio Technologies, Vista, USA). The 
high-resolution, digital images of each tissue core were annotated with respect to the 
outcome of IHC staining. TMA production, IHC staining, section scanning and annotation 
were performed at the Human Protein Atlas facilities at Rudbeck Laboratory at Uppsala 
University and in accordance with their standards [256,257].  
ER, PR, cyclins and cytokeratins (CK) were annotated at the following levels: 0-1%, 2-10%, 
11-25%, 26-50%, 51-75% and >75%. Ki-67 were annotated at 0-1%, 2-10%, 11-14%, 15-
20%, 21-30%, 31-40%, 41-50%, 51-75% and >75%. Her2 was annotated at 0, 1+, 2+, and 3+. 
Her2 SISH was performed on an automated Ventana BenchMark ULTRA IHC/ISH 
Staining Module (Ventana Medical Systems, Inc., Tuscon, AZ, USA) and was encounted in 
<4 dots, 4–6 dots and >6 dots (including clusters). Cut-offs for defining positive expression 
and the antibodies and probes used are presented in Table 4. 
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Table 4. Cut-offs for antibodies and probes used for protein and gene expression 
 
Out of the 1158 women included in the cohort for Study II, 20 were not operated on, 122 
tumor blocks were not found, 15 blocks had no tumor left in them, and there was one missed 
consent to use tumor material. Thus, 1000 women were included in the TMA. For the 
analyses, only women with stages I–III were included (excluding 38 women with stage IV 
disease), leaving 983 women with tumor material available for analysis out of the 1120 
potentially includable women (88%). 
 
Definition of subtypes 
For Studies II–IV, we used surrogate definitions based on central IHC re-evaluation of ER, 
PR, Ki-67 and Her2 according to the St Gallen Consensus Statement [48,261].  
Luminal A  ER+, PR+, Her2- and Ki-67 low 
Luminal B  ER+, PR+, Her2- and Ki-67 high or  
ER+, PR-, Her2- and any Ki-67 
Luminal-Her2+ ER+ and Her2+, any PR or Ki-67 
Her2+   ER-, PR- and Her2+, any Ki-67 
Triple negative  ER-, PR- and Her2-, any Ki-67 
 
 
Statistical analysis 
Study I: The end-point was the 5-year relative survival ratio (RSR) [262]. The observation 
time was defined as the time between the breast cancer diagnosis (date taken from the 
Regional Breast Cancer Quality Registries) and death (date taken from the Total Population 
Registry). In the absence of events, patients were censored at the end of follow-up (31 
December, 2006). The RSR was calculated by comparing observed survival with expected 
 
Definition of pos staining Ref Antibody/probe/dilution 
 
Study II Study III Study IV 
  ER >10% >1% >1% [88, 89] M7047, 1:150, Dako, Glostrup, Denmark 
PR >10% >25% >25% [102, 258] M3569, 1:1000, Dako, Glostrup, Denmark 
Ki-67 >20% >14% >14% [48, 119] M7240, 1:200, Dako, Glostrup, Denmark 
Her2 IHC 3+, 2+ 3+, 2+ 3+, 2+ [107, 259] A0485, 1:1000, Dako, Glostrup, Denmark 
 
if SISH+ if SISH+ if SISH+ 
  Her2 SISH >6 dots >6 dots >6 dots [107, 259] INFORM HER2 Dual ISH DNA Probe Cocktail 
Cyclin A2 
 
>10% 
  
CAB000114, 1:200, Novocastra, Germany 
Cyclin B1 
 
>10% 
  
CAB000115, 1:1000, Transduction Lab, USA 
Cyclin D1 
 
>10% 
  
CAB000024, 1:20, Novocastra, Germany 
Cyclin E1  >10%   CAB000308, 1:200 Pharmingen, USA 
CK5/6  
  
>10% [260] M7237, 1:1000, Dako, Glostrup, Denmark 
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survival of the general population, represented by all women matched for age, calendar period 
and county of residency.  
 
To use relative survival in a large cohort like this has an advantage, cause of death is not 
required, and still can it provide a measure of mortality irrespective of cause of death. Data for 
calculating county-specific life tables were taken from Statistics Sweden 2008 [18].  
 
To investigate the possible age-related differences in prognostic factors (tumor size, lymph 
node status and hormonal status) we used Fisher’s exact test to test the independence between 
age and dichotomized variables. Excess mortality was modelled using the Poisson regression 
[263] to calculate differences in survival by age and important confounders such as stage, year 
of diagnosis, tumor size, lymph node involvement, grade, hormonal receptor status, 
multifocality, breast surgery and intended adjuvant systemic and locoregional treatment. 
Women aged 50-69 were used as a reference group. Cumulative RSR by stage was performed 
to study age differences across this variable. A multivariate analysis was performed, adjusted 
by year of diagnosis, stage at diagnosis and oncological treatment and stratified on tumor 
characteristics to evaluate the independent effect of age on survival.  
 
Furthermore, we studied differences in survival between the age groups in stages I–IIb while 
adjusting for the potential determinants by modelling the excess mortality (RER) using a 
Poisson regression analysis. In order to assess the effect of the different variables separately, as 
well as in addition to each other, five separate models were constructed. SAS 9.1 software was 
used for all statistical analyses. 
 
Study II: Endpoints were breast cancer-specific survival (BCSS), distant disease-free survival 
(DDFS) and locoregional recurrence-free survival (LRFS). All survival estimates were 
calculated from the date of diagnosis to the date of event or, in absence of an event, to the 
end of follow-up, recorded individually, but, at latest, the end of 2012. An event for BCSS 
was defined as death from breast cancer, for DDFS as a distant recurrence or death from 
breast cancer and, for LRFS, as a locoregional recurrence as the first event prior to distant 
recurrence. No censoring was done for invasive or non-invasive contralateral breast cancer.  
 
Associations between variables were evaluated using the Pearson Chi-2 test. Survival curves 
were derived from Kaplan-Meier estimates [264] since death from other cause than breast 
cancer was uncommon in this population. Survival curves were compared using the log-rank 
test [265]. Cox proportional-hazard models were used to estimate univariate and multivariate 
hazard ratios (HRs) with 95% confidence intervals (CIs). IBM SPSS Statistics v22.0 (SPSS 
Inc., Chicago Illinois, USA) was used for all statistical analyses. 
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Study III: The endpoint was DDFS, as defined in Study II. All statistical methods used were 
the same as in Study II. IBM SPSS Statistics v24.0 (SPSS Inc. Chicago, Illinois, USA) was 
used for all statistical analyses. 
 
Study IV: The primary endpoint was the probability of Her2-positivity by IHC and SISH. 
The secondary endpoint was BCSS (as defined in Study II), predicted by either method. For 
probabilities of test accuracy, the likelihood ratio test was used and, for the calculation of 
post-test probabilities, Fagan´s nomogram [266]. Distributions and associations between 
variables were evaluated with the Pearson Chi-2 test. Survival analyses were derived using 
Kaplan-Meyer estimates and compared using the log-rank test. Cox proportional-hazards 
models were used to estimate hazard ratios. Likelihood ratios, posterior probabilities and 95% 
CIs were calculated using a Diagnostic Test Calculator [267]. All other calculations were 
performed using IBM SPSS Statistics v24.0 (SPSS Inc. Chicago, Illinois, USA).
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RESULTS 
 
Study I - Women with breast cancer diagnosed before age 35 have a more advanced disease and 
receive a more intense treatment, but, still, they have a worse prognosis compared to women aged 
50–69 
In this large population-based cohort of women aged 20–69, only 2.1% of the women was 
aged <35 at breast cancer diagnosis and only 6.0% aged <40. Compared to women aged 50–
69, women aged <35 had larger tumors and more often with lymph node involvement and 
stage III–IV at diagnosis (Figure 4).  
Figure 4. Stage 
distribution in 22,017 
women diagnosed with 
primary invasive breast 
cancer. 
 
Variables describing tumor biology had a high proportion of missing data, although 
indicating more aggressive characteristics, more often grade III, hormone receptor negativity 
and multifocality. Treatment (as by intention to treat) was more intense in women aged <35, 
with a higher rate of mastectomies and planned chemotherapy more than twice as often, 
whereas no age-related differences in planned endocrine treatment or radiotherapy were 
noted.As for survival estimates, the 5-year survival, measured by the relative survival ratio 
(RSR), was much lower in women aged <35 (74.8%) than in those aged 50–69 (90.7%) 
(Figure 5).  
Figure 5. Relative 
survival ratio (RSR) by 
age at diagnosis. 
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When translated into risk as expressed by the relative excess ratio (RER) using women aged 
50–69 as reference, women aged <35 had 2.8 times as high a risk of dying within 5 years from 
a breast cancer diagnosis. When stratified by stage at diagnosis, the excess risk of dying for 
women aged <35, compared to those aged 50–69, was highest in the early stages and most 
pronounced in those with the smallest tumors, i.e., measuring only 1–10 mm. For women in 
stage III, there were no age-related differences in survival. 
 
When analysing tumor size, lymph node status and hormonal receptor status, one by one, 
and adjusting for the other two factors, age <35 was an independent risk for death due to 
ER+PR+ tumors, regardless of tumor size or lymph node status, but not for ER-PR- tumors. 
A subgroup analysis of women with stage I, with tumors <10 mm, showed that women aged 
<35 were scheduled for a very intense treatment with more mastectomies, chemotherapy and 
endocrine therapy more often than for women aged 50–69. Women aged <35 with 11–20 
mm tumors were scheduled more often for chemotherapy. There were no differences in 
planned radiotherapy for women of different ages with stage I tumors sized 1–20 mm. The 
combined effect of prognostic factors for women with stage I-IIb tumors was modelled in a 
Poisson regression where the unadjusted excess risk of death for women aged <35 was 3.6 
times as high risk of women aged 50-69. After adding explanatory variables separately (year 
of diagnosis, stage, grade, hormonal receptor status, multifocality, type of surgery, 
radiotherapy, chemotherapy and endocrine treatment), age <35 was an independent risk 
factor for death, conferring an increase that was 1.8 times as high as for women aged 50–69. 
 
 
Study II – In early stages of breast cancer, age <40 is an independent risk factor for distant and 
locoregional recurrence. Age <40 entails a higher risk of breast cancer death of the Luminal B subtype, 
but not in the other subtypes. 
 
At a median follow-up of 10 years, 20.2% of the women aged <35 had had a locoregional 
recurrence. Corresponding figures for women aged 35–39, 40–49 and 50–69 were 19.5%, 
14.1% and 7.5%, and a distant recurrence had occurred in 40.0%, 31.1%, 24.5% and 14.3%, 
respectively. 
Women aged <35 had larger tumors, more often positive lymph nodes, more often tumor 
grade III, ER-, PR-, Her2+, high Ki-67, presence of LVI, multifocality and EIC. Compared 
to women aged 50–69, the subtype distribution in women aged <35 showed Luminal A less 
often and TN and Her2+ subtypes more often. Reflecting differences in stage distribution 
and tumor biology, breast cancer treatment was more intense in women aged <35 and they 
had more often mastectomies and more often chemotherapy, which more often included the 
new drugs of the time, such as taxanes and neoadjuvant chemotherapy. Trastuzumab was 
introduced during the study period and was given to very few women. Chest wall 
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radiotherapy after mastectomy was given almost twice as often to women aged <35, whereas 
endocrine therapy was given as often as to women aged 50-69. 
Breast cancer specific survival, taking only age into consideration, showed that women aged 
<35 had an almost 3-fold risk and women aged 35–39 a more than 2-fold risk of dying from 
breast cancer, compared to women aged 50–69 (Figure 6).  
 
Figure 6. Breast 
cancer-specific survival 
by age for 1120 women 
stage I-III. 
 
 
Among the risk factors for breast cancer-specific deaths among women aged <35, as 
compared to those aged 50–69, tumor size <20 mm, stage I, grade I–II and Luminal B 
subtype were identified. For women aged 35–39, the risk pattern was quite similar to that of 
women aged <35, whereas women aged 40–49 had risks similar to those of women aged 50–
69. In the multivariate analysis, adjusting for year, stage, screening detection, grade, subtype 
and systemic treatment, age <35 and age 35–39 were independent risk factors for locoregional 
recurrence, but not for breast cancer specific survival (BCSS) or distant disease-free survival 
(DDFS).  
 
In a subgroup analysis of women in stage I-IIa, split at age 40, age <40 was an independent 
risk factor after all adjustments for distant (HR, 1.87; 95% CI, 1.03–3.44; p=0.042) and 
locoregional recurrent disease (HR, 4.10; 95% CI, 2.20–7.66; p <0.001) (Figure 7). 
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Figure 7. Forest plot of multivariate Cox model describing risk of event for women with luminal 
breast cancer stage I-IIa. Women aged <40 (n=152) compared to women aged ≥40 (ref) (n=237).  
 
 
Study III –The higher expression of proliferation markers in young women does not have a strong 
impact on prognosis. Proliferation markers are less important in young women, and Ki-67 is 
prognostic only in young women with luminal tumors with PR+. Age <40 years is an independent 
factor for distant disease only in in the Luminal B PR+ subgroup. The only cyclin adding prognostic 
value beyond subtype in young women is cyclin E1. A high cyclin E1 is associated with a better 
prognosis in young women with Luminal B PR− breast cancer.  
Young women with luminal tumors had a significantly higher expression of all cyclins and 
Ki-67 than middle-aged women, while in Her2-positive tumors there were no age-related 
differences in the expression of proliferation markers. In TN tumors, cyclin A2 and E1 were 
significantly higher expressed in women aged <40. 
On studying the association between DDFS and the different proliferation markers, and not 
taking subtype or age into account, the survival analysis in the whole cohort showed a high 
expression of Ki-67, cyclin A2 and cyclin E1 to be significantly associated with a worse 
outcome (Ki-67; p<0.001; cyclin A2; p=0.014; cyclin E1; p=0.030). In young women no 
proliferation marker was prognostic, not in general, nor in analyses restricted to only luminal 
tumors. For middle-aged women, a high cyclin D1 expression was associated with a better 
outcome (p=0.002). 
A univariate Cox regression analysis of risk factors for distant disease by subtype and age 
showed age <40 to be associated with a worse DDFS only in luminal tumors (age <40 years; 
HR 2.37 (1.66–3.37)).  
When we stratified luminal tumors by PR status, we found Ki-67 to be prognostic only in 
luminal PR+ tumors. When analysed with different cut-offs (14%, 20% and 30%), the lower 
cut-off was shown to have the strongest prognostic value in young women, while the higher 
cut-off was best in middle-aged women. 
0 1 2 3 4 5 6 7 8 
Hazard Ratio p-value 
(95% CI) 
BCSS crude 
2.31 (1.22, 4.38) 0.010 
adjusted* 1.47 (0.72, 3.02) 0.288 
DDFS crude 2.60 (1.51, 4.50) 0.001 
adjusted* 1.87 (1.03, 3.44) 0.042 
LRFS crude 
3.84 (2.16, 6.83) <0.001 
adjusted* 4.10 (2.20, 7.66) <0.001 
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In a multivariate analysis, high cyclin E1 remained an independent prognostic factor for a 
better outcome in young women with Luminal B PR− tumors (HR 0.47 (0.24–0.92); 
p=0.027), while high cyclin D1 remained an independent prognostic factor for a better 
outcome in women aged ≥40 with Luminal B PR+ tumors (HR 0.19 (0.05–0.74); p=0.017). 
Age <40 years was an independent risk factor for DDFS exclusively in women with Luminal 
B PR+ tumors (HR 2.35 (1.22–4.50); p=0.010) (Figure 8).  
 
 
Figure 8. Prognosis by age in women with breast cancer of the Luminal A, Luminal B PR+ and 
Luminal B PR− subtypes. 
 
To put the prognostic importance of cyclin E1 for young women with breast cancer into a 
clinical context, we performed a survival analysis of DDFS by age and subtype, dividing the 
luminal tumors into Luminal A, Luminal B PR+, Luminal B PR−/cyclin E1 high and 
Luminal B PR−/cyclin E1 low (Figure 9). Young women with Luminal B PR−/cyclin E1 
low tumors had a markedly worse prognosis, with an over 6-fold increased risk of distant 
disease (HR 6.21 (2.17-17.6)); p=0.001) compared to Luminal A tumors. 
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 Luminal A   Luminal B PR+   Luminal B PR- 
Distant disease free <40y vs ≥40y   <40y vs ≥40y   <40y vs ≥40y 
survival HR 95% CI p   HR 95% CI p   HR 95% CI p 
              
Unadjusted 1.91 (0.51-7.12) .335   2.40 (1.37-4.19) .002   2.08 (1.27-3.41) .004 
+Year 2.03 (0.55-7.59) .290   2.38 (1.36-4.18) .002   1.83 (1.10-3.06) .020 
+Stage 1.40 (0.33-5.98) .651   2.25 (1.28-3.96) .005   1.21 (0.72-2.05) .472 
+Grade 1.21 (0.27-5.46) .803   2.16 (1.22-3.81) .004   1.09 (0.64-1.87) .750 
+LVI 1.22 (0.27-5.56) .796   2.08 (1.18-3.68) .012   0.97 (0.56-1.67) .903 
+Cyclin A2, B1, D1, E1 0.66 (0.09-4.93) .689   2.42 (1.30-4.50) .005   1.15 (0.63-2.09) .648 
+Systemic treatment 0.63 (0.08-5.22) .671   2.35 (1.22-4.50) .010   1.14 (0.62-2.10) .670 
              
Proportion distant disease-free 
5y 10y 15y 
<40y 1.00 0.91 0.79 
≥40y 0.97 0.94 0.92 
Log-rank p = .326 
 Proportion distant disease-free 
5y 10y 15y 
<40y 0.79 0.68 0.64 
≥40y 0.92 0.87 0.80 
Log-rank p = .002 
Proportion distant disease-free 
5y 10y 15y 
<40y 0.73 0.58 0.51 
≥40y 0.85 0.77 0.67 
Log-rank p = .003 
No. At Risk    
<40y 33 33 20 8 121 94 50 21 94 69 39 19 
≥40y 75 70 47 20 119 109 69 24 102 87 46 9 
Luminal A Luminal B PR− Luminal B PR+ 
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Figure 9. Kaplan Meyer curves for DDFS by age and subtype. Women with missing data on cyclin 
E are excluded (n=8). 
 
Study IV – Her2-assessment with silver enhanced in situ hybridization (SISH) for all, significantly 
increases the Her2-positive rate compared to routine Her2-testing, and similarly for women aged 
<40 and ≥40. Her2 amplification is present in more than a third of cases scored 1+ with IHC. All 
Her2 amplified cases, both true positive and false negative, had a significantly worse BCSS than the 
true negative cases. 
Both young and middle-aged women had a significantly higher proportion of Her2-positive 
tumors when tested by SISH instead of routine testing with IHC plus reflex SISH for 
equivocal cases (IHC 2+); i.e. from 20.0% to 24.4% (p<0.001). The increase was similar for 
women aged <40 (25.6% to 30.3%) and ≥40 years (12.8% to 16.1%).  
On comparing the two tests, routine testing, with SISH testing, the sensitivity was 81.0% 
and the specificity 99.4%. Likelihood ratios indicated that a positive routine test considerably 
upgraded a prior clinical chance of Her2 being positive (to 98%), while a negative test 
changed the probability of Her2 being positive more modestly (to 6%). Due to a higher 
prevalence of Her2+ in women aged <40, the risk of a negative Her2 IHC (0-1+) missing a 
Her2 amplification was 1 in every 14 women and corresponding risk for women aged ≥40 
was 1 in every 25 women (Figure 10). 
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Proportion DDFS 5y 10y 15y HR (95%CI) 
LumA 1.00 0.91 0.79 1.00 (ref) 
LumB PR+ 0.79 0.68 0.64 3.06* (1.09-8.56) 
LumB PR-/E1+ 0.84 0.71 0.62 3.31* (1.11-9.90) 
LumB PR-/E1-(---) 0.62 0.44 0.41 6.21* (2.17-17.6) 
Her2+ 0.72 0.63 0.63 3.83* (1.37-10.7) 
TN 0.69 0.67 0.66 3.57* (1.29-9.90) 
No. At Risk    
LumA 33 33 20 8 142 131 89 36 
LumB PR+ 121 94 50 21 52 48 27 8 
LumB PR-/E1+ 45 38 25 12 30 25 10 1 
LumB PR-/E1-(---) 47 29 14 7 66 56 34 8 
Her2 exp 104 74 42 12 34 25 14 8 
TN 152 103 67 27 53 38 26 8 
Log-rank p = .004 Log-rank p = .001 
Proportion DDFS 5y 10y 15y HR (95%CI) 
LumA 0.95 0.93 0.88 1.00 (ref) 
LumB PR+ 0.92 0.81 0.77 2.38  (0.88-6.41) 
LumB PR-/E1+ 0.83 0.73 0.55 4.73* (1.54-14.5) 
LumB PR-/E1-(---) 0.85 0.78 0.70 4.13* (1.51-11.3) 
Her2+ 0.77 0.66 0.66 6.01* (2.09-17.3) 
TN 0.74 0.71 0.71 5.57* (2.04-15.2) 
                            < 40 years                                      ≥ 40 years 
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Figure 10. Likelihood ratios for Her2 routine testing and SISH, respectively, and corresponding 
histological examples of paired Her2 IHC and SISH stainings. 
 
Her2 amplification was present in 4.6% of cases scored 0 with IHC, while corresponding 
proportions for scores 1+, 2+ and 3+ were 36.0%, 83.7% and 96.8%. Her2 had a prognostic 
value regardless of it was assessed by IHC (3+ vs 0-1+, HR 1.51, p=0.028), Her2 gene copy 
numbers (>6 dots vs <4 dots, HR 1.60; p=0.005) or Her2 gene amplification (amplification vs 
no amplification, HR 1.55; p=0.008). When the Cox regression analysis were stratified by 
age, Her2 status was not a risk factor for BCSS in women aged <40, but for women aged ≥40 
with Her2 status expressed by SISH copy numbers or amplification (HR 2.69 (1.46-4.97); 
p=0.001 and HR 2.88 (1.54-5.40); p=0.001).  
Compared to true positive cases, false negative cases more often had ER-positive, CK5/6-
positive, lymph node-negative disease, which was less often multifocal. On comparing BCSS, 
did the true negative cases have the best survival, followed by the true positive cases (HR 1.45 
(1.03-2.05); p=0.033), whereas the false negative cases had the worst survival (HR 2.06 (1.19-
3.58); p=0.010) (Figure 11).  
Her2 SISH 
Amplified Not amplified 
Her2 
routine 
Pos 
162 
True pos 
4 
False pos 
38 
False neg 
625 
True neg 
Her2 
routine 
Neg 
Sensitivity 81.0% 
(74.7% to 86.1%)  
Specificity 99.4% 
(98.3% to 99.8%) 
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Figure 11. Breast cancer-specific survival by Her2 status in 804 women untreated with 
trastuzumab. 
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DISCUSSION 
 
Young age as a risk factor for poorer survival in breast cancer was suggested as early as in the 
1930s [268], with increasing attention to the phenomenon in the 1980s [1,269]. With the 
development of national registration of diseases, the search for evidence in medicine has been 
facilitated, making it easier to draw conclusions, especially concerning rare diseases, among 
which we reckon breast cancer in young women. With highly validated data in many 
registers, the possibility of identifying differences within a population and then adjusting for 
them one by one, using epidemiological strategies, there is a prospect of coming closer to the 
truth. The prognosis in breast cancer is age-dependent since different factors influence 
survival in different age groups.  
The best survival from breast cancer is seen in women aged 40-49 years. These women are 
included in screening programmes and thereby have their breast cancers detected early. The 
impact of co-morbidity is low. A large population-based study on elderly women with breast 
cancer, generated from the same regional breast cancers as in our cohort, showed that women 
aged >70 (which not are included in screening programs) had a worse survival compared to 
women aged 50-69 subjected to less diagnostic activity, a later stage diagnosis and less intense 
treatment [270]. This research arose from the hypothesis that low age could not possibly be a 
true risk factor, but only a proxy. The aims of this thesis therefore became to identify risk 
factors for young women with breast cancer by comparing different variables across age 
groups and thereby to find an explanation for why the young women do worse became the 
aim of this thesis.  
Methodological considerations 
Internal validity is crucial to being able to draw conclusions from data. A high internal 
validity is dependent on the absence of systematic errors such as bias and confounding. Bias is 
an exposure that influences the risk of the outcome. Selection bias, could for example be 
introduced if certain age groups are registered in the National Breast Cancer Quality Registry 
less often. The Registry is, however, continuously validated by updates from the Swedish 
Cancer Registry, as well as the Swedish Causes of Death Registry and is therefore influenced 
to a low degree by bias. In our study, we included age groups in which the validity is good 
(not including women aged >75), for whom validity is known to be less good. Diagnostic 
bias might possibly have influenced the results in Study I since women aged <40 were not 
included in screening programmes. In Study I, the multivariate analysis was adjusted for 
stage, and in Study II for both stage and detection mode (in Study II data on the detection 
mode were extracted from the medical records). 
Confounders are variables associated with outcome independently from the exposure and 
should be distributed differentially among the exposed and the un-exposed. In Studies I-IV 
 40 
we have searched for possible explanatory variables and tried to adjust for them by both 
stratification and regression analyses. The DAGitty is a graphical tool for drawing causal 
diagrams [271] (Figure 12). The third common way to control for confounding, matching of 
cases, is not used in these studies. 
 
Figure 12. Causal 
diagram 
(DAGitty) 
illustrating the 
relation between 
variables of 
exposure (young 
age) and outcome 
(breast cancer 
death).  
 
 
Loss to follow-up in Study I was minimal due to the mandatory reporting to the Swedish 
Causes of Death Registry, with which The National Breast Cancer Quality Registry data 
were matched. In Studies II-IV there were no missing data on cause of death but for 8 of 
1171 women lost to follow-up in medical records, there might have been unnotified local 
recurrences.  
Missing data on variables in Study I were evenly distributed between the age groups, except 
for tumor size, which was missing more often in women aged <35. Young women do more 
more often have locally advanced disease and thereby a less well-defined tumor size. Stage 
was missing more often in women aged 50-69. In our cohort, women with undefined stage 
had a survival resembling that of women in stage I-IIa. In Study II, information collected 
from the medical records ensured a more complete data set. We found that, despite a 60% 
missing of stage in Study I, the proportion of grades I, II and III, respectively, was nearly the 
same as in Study II, indicating that the missing data did not introduce a bias. There was a 
very high concordance between intention-to-treat data in Study I and the actual treatment 
given in Study II. The single difference noted was that more intense treatment; especially 
chemotherapy, had been given to women aged <40 (Table 5). 
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Table 5 Proportions of planned treatment in Study I compared to that given in Study II. 
 
External validity, i.e., the ability to generalize the findings of these studies to another 
population, we consider high due to the population-based design maintained throughout 
Studies I-IV. 
 
Study I 
We found that age <35 when diagnosed with breast cancer was an independent risk for death 
in early stages of the disease. The age-related differences in survival were most pronounced in 
women with small tumors without lymph node involvement. This could have multiple 
explanations. Women aged 50-69 (and to some extent also women aged 40-49) had a high 
proportion of early, screening detected tumors. Screening detection per se has been shown to 
be a good independent prognostic factor.  
A small tumor size could also mean different things in young vs old women. In the group of 
small tumors we hypothesized that the different age groups had differing proportions of 
multifocal tumors and tumors with extensive DCIS, but only a small invasive foci. This was 
addressed in Study II where multifocality and EIC could be eradicated as risk factors. 
Instead, we found an absence of multifocality and EIC to be a risk, and perhaps the presence 
of these factors influenced treatment decisions towards more extensive locoregional and 
systemic treatment.  
Furthermore, no differences in survival were seen between tumors in advanced stages or in 
those with hormone receptor-negative tumors. Based on these findings we hypothesized that 
women with more advanced stage and hormone receptor-negative disease, regardless of age, 
reeived intense treatment, thereby reducing the differences between age groups. This 
hypothesis was strengthened by the study by Kroman et al. suggesting that age-related 
differences in survival were only present in women not receiving chemotherapy [2]. 
Tumor biology appeared to be a possible explanation for the findings in Study I, but the 
tumor biology-related variables available in the registry were few in number and there was a 
Age 
 
BCS 
Radio-
therapy 
when BCS 
Radio-
therapy 
Endocrine 
therapy 
when ER+ 
Proportion 
neoadjuvant 
Chemo-
therapy 
<35 Study I 44.8% 91.9% 71.1% 69.0% 14.0% 65.2% 
 
Study II 46.3% 95.1% 80.4% 70.4% 17.1% 75.5% 
        35-39 Study I 48.1% 93.7% 74.2% 65.2% 13.5% 60.8% 
 
Study II 49.5% 97.9% 78.4% 62.0% 15.3% 74.7% 
        40-49 Study I 55.5% 93.5% 75.3% 64.8% 8.5% 46.2% 
 
Study II 60.9% 96.6% 83.3% 62.2% 6.8% 46.4% 
        50-69 Study I 63.8% 92.4% 75.5% 72.8% 4.3% 26.5% 
 
Study II 66.2% 96.4% 78.8% 75.0% 2.7% 30.4% 
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large amount of missing data on important variables. The missing data on tumor 
characteristics was evenly distributed across age groups.  
Data on the type of surgery was recorded as given treatment with less than 0.5% missing. 
Systemic treatment was reported as intention-to-treat, and the proportion of missing data 
was not recorded. Endocrine treatment was planned in only 65-70% of the women with ER+ 
tumors, irrespective of age, which is considered to be under-treatment by today’s standards. 
Endocrine therapy was not recommended for women with tumors <1 cm or for 
premenopausal women until the end of the study period. 
In the light of the contemporary St Gallen Guidelines, age <35 was an indication for 
chemotherapy, but was only planned for 34% of the women aged <35 in stage I within our 
study. The proportion of women scheduled for chemotherapy was, however, much higher for 
women aged <35 and 35-39 than for middle-aged women, indicating that tumor biological 
characteristics or low age in itself was indications for the more intense systemic therapy 
planned in this early stage.  
To conclude, we found that stage at diagnosis could partly explain the worse survival in young 
women, but that the remaining independent prognostic impact of age was most likely only a 
proxy for aggressive tumor biology. 
 
Study II 
Study II was designed for further in-depth studies of age-related differences in prognosis 
based on the results from Study I. We aimed to study the same research question but now 
including several variables on tumor characteristics not available in the registers, e.g., data on 
parity, pregnancies and heredity, as well as data on treatment with a complete long-term 
follow-up. The design also enabled a validation of all variables from the registry previously 
studied, but with a large proportion of missing data. By collecting detailed clinical data and 
enabling new analyses of archival tumor tissue, we hoped to dismiss low age as a risk for 
breast cancer death and instead get insight into the biological explanation behind the 
association between age and outcome. 
The finding that women aged <35 and women aged 35-39 share the distribution of tumor 
characteristics, risk profiles and survival outcomes is interesting from a biological point of 
view. One factor that can influence the prognosis in young women, but not in middle-aged 
ones, is whether the tumor arises during, or whithin, a year of pregnancy (PABC). On 
reanalysing data from Study II, PABC was found to be an increased risk for BCSS in women 
aged <35 (60 PABC of 440 women aged <35; 13.6%) (HR 1.70 (1.12-2.59); p=0.013) but 
not in women aged 35-39 (12 of 182; 6.6%) or women aged 40-49 (2 of 189; 1.1%). 
Including PABC in the multivariate model did not change the main findings. Another factor 
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that only influences women aged <40 is that they are not included in screening 
mammography, which we adjusted for in the multivariate model.  
 
The finding of similarities between women aged <35 and 35-39, and the fact that women 
aged 40-49 had only one risk factor that differed between them and those aged 50-69 (PR-
negativity was a risk for women aged 40-49), reassured us that combining the two youngest 
and the two oldest age groups would not introduce any substantial bias. This strategy was 
later also used for Studies III and IV.  
One finding in Study II was the increased risk of locoregional recurrence (LR) in young 
women. Women aged <40, stage I-III, had twice as high a risk of LR as women aged ≥40, 
which is in line with earlier publications [212,218]. We know that women with advanced 
stage, Her2+ and TN breast cancer are at higher risk of LR, but also when the analysis is 
restricted to women with luminal Her2-negative early disease, the risk for women aged <40 
having a LR as first event was 4-fold higher compared to those aged ≥40. 
We have chosen not to use disease-free survival, but instead locoregional recurrence-free and 
distant recurrence-free survival in our studies, knowing the comparably higher risk of LR in 
young women than in middle-aged women, so as not to mix the two different events. 
Absolute figures of locoregional and distant recurrences are shown in Figure 13.  
On analysing all women, regardless of stage or subtype, women aged <40 had LR as the first 
separate event twice as often as women aged ≥40 (20% vs 10%). The corresponding figures 
for distant disease or breast cancer death, as the first event was 24% vs 14%. Women aged 
<40 had distant disease or breast cancer death twice as often as women aged ≥40 (36% vs 
18%). The proportion of women remaining disease-free after a LR was 40% vs 55%. Possibly, 
the LR was a chance to receive a second-try adjuvant round of treatments, which substantially 
decreased the risk of a later distant recurrence.  
 
Figure 13. LRFS and DDFS in women stage I-III.  
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In Study II, we still found young age to be an independent risk factor for distant and 
locoregional recurrence in early stages of disease, but now restricted to tumors with luminal 
(Her2-negative) biology. 
 
Study III 
In the design of the cohort for Studies II-IV, one of the aims was to find new prognostic 
markers for the young population. With the findings from Study II regarding age-related 
differences in prognosis being restricted to luminal tumors, we decided that the first group of 
prognostic markers to be addressed were proliferation markers since they constitute the main 
water-shed in the division of the Luminal A vs Luminal B subtypes.  
Cyclins were discovered in the mid-1990s and showed promising results as prognostic 
markers in breast cancer and with an age-specific expression. Since subtypes made their 
entrance in the prognostic arena, the value of cyclins has been investigated only by a few 
authors [122-124] and never in a population-based material.  
We extended our earlier analyses of IHC markers (ER, PR, Ki-67, Her2, CK5/6) from 
Study II with analyses of cyclins A2, B1, D1 and E1. To mimic the clinical situation and 
reveal the prognostic impact of proliferation markers within different subtypes, we stratified 
our analyses by subtype (Luminal Her2-negative, Her2+ and TN).  
The main findings were: Proliferation markers are significantly more highly expressed in 
women aged <40, but they do not have a strong impact on prognosis. Ki-67 was prognostic 
only in young women with Luminal PR+ tumors. The optimal cut-off for Ki-67 as a 
prognostic marker in luminal PR+ tumors was lower for younger women than for middle-
aged ones. Age <40 was an independent risk factor for a worse DDFS in women with 
Luminal B PR+ tumors. Cyclins added only limited prognostic value, except in young women 
with Luminal B PR− breast cancer, a subgroup with a sinister prognosis, where a high 
expression of cyclin E1 was associated with a statistically significant better prognosis.  
On considering the results from our Study III, the absence of standardized methods for 
measuring Ki-67 and the question of reproducibility of the results are crucial. One of the 
strengths of this study is the central re-evaluation of Ki-67 which was performed in this 
population-based material with tumor tissue from such a large proportion of the women 
included. While it has been shown that protein expression of ER, PR and Her2 on archival 
TMA cores highly correlates with the analysis of whole sections [272], the analysis of Ki-67 
on tissue cores has been shown to generate a generally lower Ki-67 score than analyses of 
whole sections [273]. Also, the way Ki-67 is assessed matters. Focke et al. showed that the 
higher the number of cells counted in luminal tumors, the lower where Ki-67 scores and thus 
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the higher were the proportion of Luminal A tumors [274]. We analysed Ki-67 on duplicate 
cores from each patient, read in hotspots. Since the main goal of this study is a comparison 
between age groups, a potential bias derived from a low Ki-67 count on TMA cores, should 
not in any major way affect our results. On the contrary, Ki-67 in our cohort was comparably 
high, corresponding to the age profile in the cohort. A rule of thumb is that in a ‘normal 
breast cancer population’ 1 out of 3 tumors should be considered to be highly proliferating. 
On applying this rule to our cohort in Study III and defining women aged 50-69 as normal, a 
Ki-67 cut-off of 30% will produce a proportion of 69% slowly proliferating tumors. This 
strengthens the assumption that the optimal cut-off of Ki-67 for prognostic use is 30% for 
women aged ≥40 years.  
Age remains an independent negative prognostic factor in Luminal B PR+ breast cancer, 
with a more than two-fold risk of distant disease compared to middle-aged women with 
corresponding stage and biology. This is a clinically highly relevant finding which has to be 
considered in treatment decisions. One explanation for this finding may be endocrine 
resistance, which is noted more often in young women in studies on gene expression 
signatures related to endocrine resistance [222]. Young women are less adherent to endocrine 
therapy which might be another explanation [191,192].  
With these results, we draw the following conclusions concerning women aged <40 with 
luminal tumors; (1) PR-negativity is an important marker of a worse survival; (2) the optimal 
cut-off for defining a Luminal A tumor in PR+ tumors is sooner 14% than 20% or 30% and 
(3) the Luminal A subtype is very uncommon in young women, and the separation from the 
Luminal B subtype is even more difficult than in middle-aged ones, and perhaps gene-based 
subtyping should be used for these women. The question is raised as to whether a classic 
Luminal A subtype accompanied by a good prognosis actually exists in women aged <40 since 
the 15-year distant disease-free survival in the young women with Luminal A tumors (79%) 
is about the same as that seen in middle-aged women with the Luminal B subtype (80%). 4) 
Further studies are needed to clarify the explanation behind the divergent prognosis in young 
and middle-aged women with Luminal B PR+ tumors despite more intense treatment in 
young women. With current biomarkers and tumor characteristics used in clinical routine, we 
found no significant differences between the age groups. 
 
Study IV 
The main findings were: 1) A significantly higher proportion of Her2-positivity was 
generated by SISH-analysis in all women, compared to routine testing with IHC followed by 
SISH only for those equivocal (IHC 2+). Her2 routine testing led to a missed Her2-positivity 
in every 14th woman aged <40 and every 25th in those aged ≥40. We deem the clinical utility 
of this finding to be high since in real-life breast cancer care, every case of early Her2-positive 
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breast cancer nowadays has a good chance of cure due to targeted therapies developed against 
the Her2 receptor. 2) All Her2 amplified cases, both true positive and false negative, had a 
significantly worse BCSS than the true negative cases. 
A Her2 IHC score of 3+ had a very high correlation to Her2 amplification by SISH (96.8%), 
a statement also true for those who scored IHC 2+ (83.7%). The unexpected finding was 
that, among the cases scoring IHC 1+, 36.0% were, in fact, Her2-amplified. In the 
pathological routine assessment of Her2 status, the judgment as to whether a case scores 1+ 
or 2+ by IHC can be very difficult, and often involves a second opinion by another 
pathologist.  
With the results from Study IV it seems obvious to suggest a changed routine to perform 
Her2 SISH for both cases with Her2 IHC score 1+ and 2+. It can also be added that the 
proportion of cases scoring 1+ using Her2 IHC is small, especially after the new assessment 
guidelines by ASCO/CAP from 2013 [275,276], and would accordingly not be very 
expensive. In situ hybridization is however, in comparison to IHC, more expensive, has 
higher failure rates, takes a longer time both to test and interpret [277]. We also observed a 
high failure rate of SISH (SISH-analysis ending uninformative). Of 939 cases eligible for the 
study (all having information on Her2 IHC), 110 (12%) failed the SISH test and were 
excluded. The failure rate in our material is in line with Dybdal et al. having a 15% failure 
rate [278]. Of the 110 cases uninformative with SISH, 100 had IHC score 0, seven had score 
1+, one had score 2+ and two score 3+. Assuming these cases were amplified to the same 
extent as those included in the analyses, the Her2 positive rates would have been 17.7% with 
routine test and 22.4% with SISH; thus the difference between the methods would have been 
the same as when we restricted analyses to only informative cases (20.0% vs 24.1%).  
The false negative rate in our study was relatively low (38 of 829; 4.6%); however, for these 
38 women, hypothetically, a positive Her2 test could have changed their prognosis to the 
better thanks to the targeted anti-Her2 treatments offered to women with Her2 positive 
tumors today.  
The false negative cases were more often ER+, which is in concordance with findings by Lee 
et al. indicating tumors with high intratumoral heterogeneity and inaccurate Her2 assessment 
are more frequent in the Luminal-Her2+ subtype [279]. Multifocality can also increase the 
risk of intratumoral heterogeneity and is more often present in Luminal-Her2+ tumors 
[280,281]. We tried to overcome intratumoral heterogeneity by viewing duplicate cores from 
each case and performing both IHC and SISH at the same laboratory and on consecutive 
sections of the TMA tumor block. According to the current evidence analyzing Her2 status 
only on the largest tumor foci is safe as long as the smaller concomitant foci do not differ in 
histological type or tumor grade [282].  
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In our study were the false negative cases more often CK5/6 positive. Cytokeratins indicate a 
basal phenotype, and CK5/6-positive, Her2+ tumors are associated with worse prognosis and 
a high proportion of non-responders to targeted therapy [260,283,284].  
When comparing the prognosis between the true negative, the true positive and the false 
negative cases, the true positive cases had, as expected, a worse BCSS than the true negative 
cases (HR 1.45 (1.03-2.05)). The false negative cases did also have a worse prognosis than 
the true negative ones (HR 2.06 (1.19-3.58)), however, not statistically significantly different 
from the true positive cases (p=0.362).  
As expected, we found Her2 status not to be a prognostic factor in young women. Young 
women have an over-representation of the aggressive subtypes Luminal B and TN, which 
have about the same outcome as seen in Her2+ subtypes. On the contrary, Her2-status was 
clearly prognostic in women aged ≥40 with a subtype distribution dominated by Luminal A 
and Luminal B, both associated with a better survival.  
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CONCLUSIONS 
 
• Women with breast cancer diagnosed before age 35 have a more advanced disease at 
diagnosis. They receive a more intense treatment, but still have a worse prognosis 
than women aged 50-69. 
 
• In luminal (ER-positive, Her2-negative) breast cancer there is a significantly different 
distribution of both tumor characteristics and prognosis between young and middle-
aged women.  
 
• Tumor characteristics as well as prognosis are very similar for young and middle aged 
women with the Her2 positive and triple-negative subtypes. 
 
• In early luminal breast cancer, age <40 is an independent risk factor for distant and 
locoregional recurrence. The risk for young women compared to middle-aged women 
to have a distant recurrence is 2-fold, and to have a locoregional recurrence 4-fold. 
Age <40 confers a higher risk of breast cancer mortality in women with tumors of the 
Luminal B subtype, but not in other subtypes. 
 
• Proliferation markers are important only in luminal tumors, where they are 
significantly higher expressed in women aged <40. They do not have a strong impact 
on prognosis. Ki-67 has a prognostic value in luminal tumors, restricted to the 
luminal PR+ group. Age <40 is an independent risk factor for distant disease only in 
women with tumors of the Luminal B subtype being PR+. 
 
• The prognostic value of cyclins are restricted to luminal tumors. For women aged <40 
with luminal PR− tumors (18% of the young population), a high cyclin E1 was an 
independent marker for decreased risk of distant recurrence. 
 
• Her2 status examined by silver in situ hybridization (SISH) generates a higher 
proportion of Her2 positive cases than routine testing with immunohistochemistry. In 
trastuzumab-untreated women Her2 was a strong prognostic marker for women aged 
≥40, but had no value as a prognosticator in women aged <40.
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FUTURE PERSPECTIVES 
 
The observations made, and conclusions drawn in this thesis are based on historical data, 
which is a prerequisite to obtain a long follow-up. During the period from 1992 and until 
2005, diagnostics and treatment of breast cancer has undergone dramatic changes. Breast 
cancer screening became fully implemented and treatment regimes changed according to 
evidence-based studies. The survival rates increased for all women, but most for middle-aged 
women, which concomitantly increased the differences in outcome between young and 
middle-aged women.  
In the 1940s young age was in itself identified as a risk factor for lower survival in breast 
cancer. Later were age-related differences in survival were restricted to early stages of the 
disease, and more recently the age-related differences have been limited to women with 
tumors of the luminal (ER+/Her2−) subtypes. Gene expression profiling has identified age-
related differences in genes regulating tumor growth, immune response, mammary stem cells 
and apoptosis. With an increased insight into the biology of breast cancer in young women, 
we will most certainly discover that age is just a proxy for a combination of other factors. 
Until then some crucial questions need to be answered: 
1. Why are young women more prone to Luminal B, Her2-positive and triple-negative 
subtypes? Is the answer in the genes? 
2. Why are the age-related differences in survival restricted to women with Luminal B 
tumors expressing PR? 
3. Is the explanation for age-related differences in prognosis found in either of; stroma-
related factors, stem-cell properties, angiogenetic factors, immune response markers, 
or hormonal receptors? 
4. Can we find new biomarkers selecting young women at low risk of recurrent disease 
and thereby reduce the use of systemic therapy? 
5. Do age-related differences in survival persist in an era of modern therapies? 
6. Can young women with non-genetic risk factors for breast cancer (like breast density) 
be identified and benefit from screening? 
 
We have constructed our young breast cancer cohort with the aim to elucidate some of these 
unanswered questions, whereas other questions need new material, new cohorts and new 
collaborations to be answered. 
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SVENSK SAMMANFATTNING 
 
Målet med denna avhandling var att få en ökad kunskap om långtidsprognosen hos unga 
kvinnor med bröstcancer. 
 
I en populationsbaserad kohort bestående av 22 017 kvinnor med bröstcancer, studerade vi 
prognosen i olika åldersgrupper. Kvinnor under 35 år vid diagnos (471 st), kvinnor 35-39 år 
(858 st) och kvinnor 40-49 år (4789 st) jämfördes med kvinnor i åldern 50-69 år (15 899 st) 
med avseende på överlevnad uttryckt som relativ överrisk att dö jämfört med 
normalbefolkningen i samma åldersgrupp. Kvinnorna under 35 år hade den sämsta 
överlevnaden vilket delvis kunde förklaras av en högre andel unga med diagnos i ett senare 
skede av sjukdomen. När man kontrollerade statistiskt för skillnaden i stadium fann man att 
en sämre överlevnad för de unga endast kan ses vid diagnos i tidigt stadium.  
 
I nästa studie gick vi vidare och studerade alla kvinnorna under 35 år vid diagnos, men 
jämförde dem nu med en mindre, slumpmässigt utvald grupp om 700 kvinnor från den 
stora kohorten. För dessa kvinnor insamlades journaluppgifter om deras bröstcancer, men 
även uppgifter om barnafödande, ärftlighet, behandling och uppföljning. Arkiverat 
tumörmaterial insamlades till en tumörbank, och på detta gjordes nya tumörbiologiska 
analyser. Vi studerade risken för bröstcancerspecifik död, risken för lokalt återfall (i bröstet 
eller på bröstkorgsväggen) samt risken för återfall av bröstcancern i andra organ. När man i 
analyserna korrigerade för bl a skillnader i stadium, tumörbiologi och behandling fann vi att 
låg ålder i sig fortfarande var förenat med en högre risk att få lokalt återfall än hos kvinnor i 
åldern 50-69. Unga kvinnor med tidigt stadium av bröstcancer av östrogenkänslig typ och 
utan överuttryck av Her2-genen hade även en ökad risk för återfall i andra organ. Dessa 
kvinnor hade en nästan dubbelt så stor risk att få återfall i andra organ än en kvinna som var 
50-69 år.  
 
Fyndet att unga kvinnor med östrogen-positiva, Her2-negativa tumörer var de som hade en 
sämre prognos fick oss att gå vidare med analyser av tumörernas tillväxttakt, proliferation, en 
markör som generellt är viktig för att skilja tumörer med en bra respektive sämre prognos. På 
tumörmaterialet gjordes analyser av Ki-67 och cykliner, proteiner som indikerar hög tillväxt. 
Resultaten från föregående studie stod sig, men vi kunde nu ytterligare specificera gruppen 
med åldersskillnader i prognos till tumörer av Luminal B subtyp med känslighet för ett annat 
könshormon, progesteron. Dessa kvinnor under 40 år hade en drygt dubblerad risk för återfall 
i andra organ. Detta fynd hjälper oss att förstå vilka unga kvinnor som kan behöva mer eller 
annan behandling än vad som ges till en medelålders kvinna med samma tumörtyp. 
 
I avhandlingens sista studie studerades Her2-positiva tumörer. Dessa har en sämre prognos 
än många andra subtyper av bröstcancer, men å andra sidan finns sedan ca 10 år en 
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målinriktad behandling för dessa tumörer vilket lett till att prognosen förbättrats drastiskt. 
Her2-positiva tumörer är dubbelt så vanligt hos unga som hos äldre kvinnor. Vi jämförde två 
testmetoder som används för att diagnosticera Her2-positiv bröstcancer och fann att metoden 
som påvisar Her2-positivitet på gennivå gav en högre andel av Her2-positiva fall än 
rutinmetoden där Her2 undersöks på proteinnivå. Detta är ett viktigt fynd eftersom alla 
kvinnor som går med oupptäckt Her2-positiv bröstcancer skulle kunna få en avsevärt 
förbättrad behandling med större chans till bot. 
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